HRP20000373A2 - Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors - Google Patents
Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors Download PDFInfo
- Publication number
- HRP20000373A2 HRP20000373A2 HR20000373A HRP20000373A HRP20000373A2 HR P20000373 A2 HRP20000373 A2 HR P20000373A2 HR 20000373 A HR20000373 A HR 20000373A HR P20000373 A HRP20000373 A HR P20000373A HR P20000373 A2 HRP20000373 A2 HR P20000373A2
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- title compound
- brs
- ylsulfonyl
- mmol
- Prior art date
Links
- 239000002253 acid Substances 0.000 title claims description 16
- 239000003112 inhibitor Substances 0.000 title claims description 15
- 102000005741 Metalloproteases Human genes 0.000 title description 5
- 108010006035 Metalloproteases Proteins 0.000 title description 5
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title description 4
- 239000011159 matrix material Substances 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 390
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 210
- 238000000034 method Methods 0.000 claims description 191
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 169
- 239000000203 mixture Substances 0.000 claims description 147
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 70
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 57
- -1 2,3-dihydrobenzofuranyl Chemical group 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 44
- 239000001257 hydrogen Substances 0.000 claims description 36
- 229910052739 hydrogen Inorganic materials 0.000 claims description 36
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 35
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 33
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 32
- 239000002904 solvent Substances 0.000 claims description 31
- 238000006243 chemical reaction Methods 0.000 claims description 27
- 150000002431 hydrogen Chemical class 0.000 claims description 26
- 239000012453 solvate Substances 0.000 claims description 26
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 24
- 239000002585 base Substances 0.000 claims description 19
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 claims description 18
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical group C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 claims description 15
- 102100030416 Stromelysin-1 Human genes 0.000 claims description 15
- 101710108790 Stromelysin-1 Proteins 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 150000002148 esters Chemical class 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 208000010125 myocardial infarction Diseases 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 239000006184 cosolvent Substances 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical group CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 9
- 201000008482 osteoarthritis Diseases 0.000 claims description 9
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 8
- 229940124761 MMP inhibitor Drugs 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 8
- 206010027476 Metastases Diseases 0.000 claims description 8
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- 230000005747 tumor angiogenesis Effects 0.000 claims description 8
- 208000025865 Ulcer Diseases 0.000 claims description 7
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 7
- 230000003683 cardiac damage Effects 0.000 claims description 7
- 230000003176 fibrotic effect Effects 0.000 claims description 7
- 210000004969 inflammatory cell Anatomy 0.000 claims description 7
- 208000027866 inflammatory disease Diseases 0.000 claims description 7
- 208000002780 macular degeneration Diseases 0.000 claims description 7
- 230000001617 migratory effect Effects 0.000 claims description 7
- 208000017520 skin disease Diseases 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 230000036269 ulceration Effects 0.000 claims description 7
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000005605 benzo group Chemical group 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 230000029663 wound healing Effects 0.000 claims description 6
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 5
- 150000003512 tertiary amines Chemical class 0.000 claims description 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 208000028169 periodontal disease Diseases 0.000 claims description 4
- AEGNSAJEPASCEB-UHFFFAOYSA-N 2-[4-[4-(3-ethoxyphenyl)-3-methoxyphenyl]piperidin-1-yl]sulfonyl-n-hydroxy-2-methylpropanamide Chemical compound CCOC1=CC=CC(C=2C(=CC(=CC=2)C2CCN(CC2)S(=O)(=O)C(C)(C)C(=O)NO)OC)=C1 AEGNSAJEPASCEB-UHFFFAOYSA-N 0.000 claims description 3
- DMYSRZBLJSUUJP-UHFFFAOYSA-N 2-[4-[4-(3-ethoxyphenyl)-3-methylphenyl]piperidin-1-yl]sulfonyl-n-hydroxy-2-methylpropanamide Chemical compound CCOC1=CC=CC(C=2C(=CC(=CC=2)C2CCN(CC2)S(=O)(=O)C(C)(C)C(=O)NO)C)=C1 DMYSRZBLJSUUJP-UHFFFAOYSA-N 0.000 claims description 3
- JQFYDWDOFHGYLD-UHFFFAOYSA-N 2-[4-[4-(6-ethoxypyridin-2-yl)-3-methylphenyl]piperidin-1-yl]sulfonyl-n-hydroxy-2-methylpropanamide Chemical compound CCOC1=CC=CC(C=2C(=CC(=CC=2)C2CCN(CC2)S(=O)(=O)C(C)(C)C(=O)NO)C)=N1 JQFYDWDOFHGYLD-UHFFFAOYSA-N 0.000 claims description 3
- BWOKVQMLEBMZFQ-UHFFFAOYSA-N 2-[[4-[4-(3-ethoxyphenyl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]-n-hydroxy-2-methylpropanamide Chemical compound CCOC1=CC=CC(C=2C(=CC(=CC=2)C=2CCN(CC=2)S(=O)(=O)C(C)(C)C(=O)NO)C)=C1 BWOKVQMLEBMZFQ-UHFFFAOYSA-N 0.000 claims description 3
- JYHCJUBSWRQINP-UHFFFAOYSA-N 2-[[4-[4-(3-ethoxyphenyl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]-n-hydroxyacetamide Chemical compound CCOC1=CC=CC(C=2C(=CC(=CC=2)C=2CCN(CC=2)S(=O)(=O)CC(=O)NO)C)=C1 JYHCJUBSWRQINP-UHFFFAOYSA-N 0.000 claims description 3
- 239000007821 HATU Substances 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 3
- 125000001041 indolyl group Chemical group 0.000 claims description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000002950 monocyclic group Chemical group 0.000 claims description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- JRIUEEGXFJPYTG-UHFFFAOYSA-N n-hydroxy-2-[4-[4-[3-(2-methoxyethoxy)phenyl]-3-methylphenyl]piperidin-1-yl]sulfonyl-2-methylpropanamide Chemical compound COCCOC1=CC=CC(C=2C(=CC(=CC=2)C2CCN(CC2)S(=O)(=O)C(C)(C)C(=O)NO)C)=C1 JRIUEEGXFJPYTG-UHFFFAOYSA-N 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000005394 methallyl group Chemical group 0.000 claims description 2
- KQOMFRMJZJNRQB-UHFFFAOYSA-N n-hydroxy-1-[4-[4-(3-methoxyphenyl)-3-methylphenyl]piperidin-1-yl]sulfonylcyclobutane-1-carboxamide Chemical compound COC1=CC=CC(C=2C(=CC(=CC=2)C2CCN(CC2)S(=O)(=O)C2(CCC2)C(=O)NO)C)=C1 KQOMFRMJZJNRQB-UHFFFAOYSA-N 0.000 claims description 2
- QMYFMVWTULBAHS-UHFFFAOYSA-N n-hydroxy-1-[4-[4-(3-methoxyphenyl)-3-methylphenyl]piperidin-1-yl]sulfonylcyclopentane-1-carboxamide Chemical compound COC1=CC=CC(C=2C(=CC(=CC=2)C2CCN(CC2)S(=O)(=O)C2(CCCC2)C(=O)NO)C)=C1 QMYFMVWTULBAHS-UHFFFAOYSA-N 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 238000009109 curative therapy Methods 0.000 claims 4
- 238000011321 prophylaxis Methods 0.000 claims 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- 150000001340 alkali metals Chemical class 0.000 claims 1
- 125000005587 carbonate group Chemical group 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 519
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 204
- 239000007787 solid Substances 0.000 description 188
- 239000000243 solution Substances 0.000 description 121
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 114
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 96
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 92
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 76
- 239000000126 substance Substances 0.000 description 74
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 72
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 72
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 69
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 57
- 235000019341 magnesium sulphate Nutrition 0.000 description 57
- 239000011541 reaction mixture Substances 0.000 description 48
- 239000012074 organic phase Substances 0.000 description 42
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 40
- 229910052757 nitrogen Inorganic materials 0.000 description 36
- 238000004587 chromatography analysis Methods 0.000 description 35
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 35
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 32
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 30
- 239000003480 eluent Substances 0.000 description 30
- 238000010992 reflux Methods 0.000 description 30
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 28
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 28
- 239000003921 oil Substances 0.000 description 23
- 235000019198 oils Nutrition 0.000 description 23
- 238000010828 elution Methods 0.000 description 22
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- YBIPZPBGAGTBGK-UHFFFAOYSA-N methyl 2-chlorosulfonylacetate Chemical compound COC(=O)CS(Cl)(=O)=O YBIPZPBGAGTBGK-UHFFFAOYSA-N 0.000 description 21
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 20
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 20
- 239000012230 colorless oil Substances 0.000 description 20
- 239000000758 substrate Substances 0.000 description 20
- 102000004190 Enzymes Human genes 0.000 description 19
- 108090000790 Enzymes Proteins 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- 238000002425 crystallisation Methods 0.000 description 19
- 230000008025 crystallization Effects 0.000 description 19
- 238000003818 flash chromatography Methods 0.000 description 18
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 18
- 239000000284 extract Substances 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 229910000104 sodium hydride Inorganic materials 0.000 description 15
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical group [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 14
- 229910000027 potassium carbonate Inorganic materials 0.000 description 14
- 239000012312 sodium hydride Substances 0.000 description 14
- 239000012258 stirred mixture Substances 0.000 description 14
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 13
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 239000006185 dispersion Substances 0.000 description 12
- 239000006260 foam Substances 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 239000002480 mineral oil Substances 0.000 description 10
- 235000010446 mineral oil Nutrition 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 9
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 229960000583 acetic acid Drugs 0.000 description 8
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical group [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 239000012362 glacial acetic acid Substances 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 8
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 8
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical group CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 7
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 7
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 7
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical group [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- GUEHESDOJBMSSE-UHFFFAOYSA-M (2-aminophenyl)mercury(1+);acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1N GUEHESDOJBMSSE-UHFFFAOYSA-M 0.000 description 6
- 102100027995 Collagenase 3 Human genes 0.000 description 6
- 108050005238 Collagenase 3 Proteins 0.000 description 6
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 6
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000005984 hydrogenation reaction Methods 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 5
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 125000001246 bromo group Chemical group Br* 0.000 description 5
- 238000011097 chromatography purification Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 125000002346 iodo group Chemical group I* 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 150000003053 piperidines Chemical class 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical group [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 4
- CHCWUTJYLUBETR-UHFFFAOYSA-N (3-ethoxyphenyl)boronic acid Chemical compound CCOC1=CC=CC(B(O)O)=C1 CHCWUTJYLUBETR-UHFFFAOYSA-N 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical group C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 238000006069 Suzuki reaction reaction Methods 0.000 description 4
- 238000005804 alkylation reaction Methods 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 235000011148 calcium chloride Nutrition 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000004744 fabric Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- HVAMZGADVCBITI-UHFFFAOYSA-M pent-4-enoate Chemical compound [O-]C(=O)CCC=C HVAMZGADVCBITI-UHFFFAOYSA-M 0.000 description 4
- HVAMZGADVCBITI-UHFFFAOYSA-N pent-4-enoic acid Chemical compound OC(=O)CCC=C HVAMZGADVCBITI-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000037803 restenosis Diseases 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- 238000006619 Stille reaction Methods 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000007810 chemical reaction solvent Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- AVGAIPMGSIOHFZ-UHFFFAOYSA-N dichloromethane;2-propan-2-yloxypropane Chemical compound ClCCl.CC(C)OC(C)C AVGAIPMGSIOHFZ-UHFFFAOYSA-N 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 3
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 3
- 230000003239 periodontal effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- SIOVKLKJSOKLIF-HJWRWDBZSA-N trimethylsilyl (1z)-n-trimethylsilylethanimidate Chemical compound C[Si](C)(C)OC(/C)=N\[Si](C)(C)C SIOVKLKJSOKLIF-HJWRWDBZSA-N 0.000 description 3
- 238000001665 trituration Methods 0.000 description 3
- NLLGFYPSWCMUIV-UHFFFAOYSA-N (3-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1 NLLGFYPSWCMUIV-UHFFFAOYSA-N 0.000 description 2
- KGKAYWMGPDWLQZ-UHFFFAOYSA-N 1,2-bis(bromomethyl)benzene Chemical compound BrCC1=CC=CC=C1CBr KGKAYWMGPDWLQZ-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- PKJBWOWQJHHAHG-UHFFFAOYSA-N 1-bromo-4-phenylbenzene Chemical group C1=CC(Br)=CC=C1C1=CC=CC=C1 PKJBWOWQJHHAHG-UHFFFAOYSA-N 0.000 description 2
- SZCAORBAQHOJQI-UHFFFAOYSA-N 1-iodo-2-methoxyethane Chemical compound COCCI SZCAORBAQHOJQI-UHFFFAOYSA-N 0.000 description 2
- MNOJRWOWILAHAV-UHFFFAOYSA-N 3-bromophenol Chemical compound OC1=CC=CC(Br)=C1 MNOJRWOWILAHAV-UHFFFAOYSA-N 0.000 description 2
- FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical class C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 description 2
- WRFYIYOXJWKONR-UHFFFAOYSA-N 4-bromo-2-methoxyaniline Chemical compound COC1=CC(Br)=CC=C1N WRFYIYOXJWKONR-UHFFFAOYSA-N 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 2
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 125000006242 amine protecting group Chemical group 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical class [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- YXVFYQXJAXKLAK-UHFFFAOYSA-N biphenyl-4-ol Chemical compound C1=CC(O)=CC=C1C1=CC=CC=C1 YXVFYQXJAXKLAK-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 2
- RTKMLLZVUPKLMY-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-1-(2-methoxy-5-methylphenyl)sulfonylpiperidine-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC(=O)C1CN(S(=O)(=O)C=2C(=CC=C(C)C=2)OC)CCC1 RTKMLLZVUPKLMY-UHFFFAOYSA-N 0.000 description 2
- FTNFEHXDETWERN-UHFFFAOYSA-N n-[bis(aziridin-1-yl)phosphoryl]-2,6-dimethyl-5-[(4-propan-2-yloxyphenyl)methyl]pyrimidin-4-amine Chemical compound C1=CC(OC(C)C)=CC=C1CC1=C(C)N=C(C)N=C1NP(=O)(N1CC1)N1CC1 FTNFEHXDETWERN-UHFFFAOYSA-N 0.000 description 2
- XHXVAJHZTIXQQD-UHFFFAOYSA-N n-[bis(aziridin-1-yl)phosphoryl]-5-[(4-butoxyphenyl)methyl]-2,6-dimethylpyrimidin-4-amine Chemical compound C1=CC(OCCCC)=CC=C1CC1=C(C)N=C(C)N=C1NP(=O)(N1CC1)N1CC1 XHXVAJHZTIXQQD-UHFFFAOYSA-N 0.000 description 2
- XITQUSLLOSKDTB-UHFFFAOYSA-N nitrofen Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC1=CC=C(Cl)C=C1Cl XITQUSLLOSKDTB-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- 239000011686 zinc sulphate Substances 0.000 description 2
- 235000009529 zinc sulphate Nutrition 0.000 description 2
- RVNFQXCMRDUEBI-UHFFFAOYSA-N (2,2-dimethyl-1,3-benzodioxol-5-yl)boronic acid Chemical compound C1=C(B(O)O)C=C2OC(C)(C)OC2=C1 RVNFQXCMRDUEBI-UHFFFAOYSA-N 0.000 description 1
- RCVDPBFUMYUKPB-UHFFFAOYSA-N (3,4-dimethoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1OC RCVDPBFUMYUKPB-UHFFFAOYSA-N 0.000 description 1
- WJDZZXIDQYKVDG-UHFFFAOYSA-N (3-chloro-4-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C(Cl)=C1 WJDZZXIDQYKVDG-UHFFFAOYSA-N 0.000 description 1
- XDBHWPLGGBLUHH-UHFFFAOYSA-N (3-cyanophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C#N)=C1 XDBHWPLGGBLUHH-UHFFFAOYSA-N 0.000 description 1
- JIMVRUCDZGFJRE-UHFFFAOYSA-N (3-ethylphenyl)boronic acid Chemical compound CCC1=CC=CC(B(O)O)=C1 JIMVRUCDZGFJRE-UHFFFAOYSA-N 0.000 description 1
- KNXQDJCZSVHEIW-UHFFFAOYSA-N (3-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(F)=C1 KNXQDJCZSVHEIW-UHFFFAOYSA-N 0.000 description 1
- HJBGZJMKTOMQRR-UHFFFAOYSA-N (3-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C=O)=C1 HJBGZJMKTOMQRR-UHFFFAOYSA-N 0.000 description 1
- TYVPOLHSKGEXIH-UHFFFAOYSA-N (3-methylsulfanylphenyl)boronic acid Chemical compound CSC1=CC=CC(B(O)O)=C1 TYVPOLHSKGEXIH-UHFFFAOYSA-N 0.000 description 1
- WRQNDLDUNQMTCL-UHFFFAOYSA-N (4-ethoxyphenyl)boronic acid Chemical compound CCOC1=CC=C(B(O)O)C=C1 WRQNDLDUNQMTCL-UHFFFAOYSA-N 0.000 description 1
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- RMJHGWFYNDUDRZ-UHFFFAOYSA-N 1,3-benzodioxol-5-yloxyboronic acid Chemical compound OB(O)OC1=CC=C2OCOC2=C1 RMJHGWFYNDUDRZ-UHFFFAOYSA-N 0.000 description 1
- AAAXMNYUNVCMCJ-UHFFFAOYSA-N 1,3-diiodopropane Chemical compound ICCCI AAAXMNYUNVCMCJ-UHFFFAOYSA-N 0.000 description 1
- QKEZTJYRBHOKHH-UHFFFAOYSA-N 1,4-dibromo-2-methylbenzene Chemical compound CC1=CC(Br)=CC=C1Br QKEZTJYRBHOKHH-UHFFFAOYSA-N 0.000 description 1
- SWJPEBQEEAHIGZ-UHFFFAOYSA-N 1,4-dibromobenzene Chemical compound BrC1=CC=C(Br)C=C1 SWJPEBQEEAHIGZ-UHFFFAOYSA-N 0.000 description 1
- ROUYUBHVBIKMQO-UHFFFAOYSA-N 1,4-diiodobutane Chemical compound ICCCCI ROUYUBHVBIKMQO-UHFFFAOYSA-N 0.000 description 1
- JENANTGGBLOTIB-UHFFFAOYSA-N 1,5-diphenylpentan-3-one Chemical compound C=1C=CC=CC=1CCC(=O)CCC1=CC=CC=C1 JENANTGGBLOTIB-UHFFFAOYSA-N 0.000 description 1
- XJKNKYCGFUEJON-UHFFFAOYSA-N 1-[4-[4-(3-methoxyphenyl)-3-methylphenyl]piperidin-1-yl]sulfonylcyclobutane-1-carboxylic acid Chemical compound COC1=CC=CC(C=2C(=CC(=CC=2)C2CCN(CC2)S(=O)(=O)C2(CCC2)C(O)=O)C)=C1 XJKNKYCGFUEJON-UHFFFAOYSA-N 0.000 description 1
- AXVCRZHDBMSXJO-UHFFFAOYSA-N 1-benzhydryl-3-(4-phenylphenoxy)azetidine Chemical compound C1C(OC=2C=CC(=CC=2)C=2C=CC=CC=2)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 AXVCRZHDBMSXJO-UHFFFAOYSA-N 0.000 description 1
- BMIKJGOJWRBXBX-UHFFFAOYSA-N 1-benzhydryl-3-methylsulfonylazetidine Chemical compound C1C(S(=O)(=O)C)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BMIKJGOJWRBXBX-UHFFFAOYSA-N 0.000 description 1
- MXFPYIFJSMHMJB-UHFFFAOYSA-N 1-benzyl-4-(4-phenylphenyl)-3,6-dihydro-2h-pyridine Chemical compound C=1C=CC=CC=1CN(CC=1)CCC=1C(C=C1)=CC=C1C1=CC=CC=C1 MXFPYIFJSMHMJB-UHFFFAOYSA-N 0.000 description 1
- HDHGIPBZVLQAFL-UHFFFAOYSA-N 1-benzyl-4-(4-phenylphenyl)piperidin-4-ol Chemical compound C1CC(O)(C=2C=CC(=CC=2)C=2C=CC=CC=2)CCN1CC1=CC=CC=C1 HDHGIPBZVLQAFL-UHFFFAOYSA-N 0.000 description 1
- SJZKULRDWHPHGG-UHFFFAOYSA-N 1-benzylpiperidin-4-one Chemical compound C1CC(=O)CCN1CC1=CC=CC=C1 SJZKULRDWHPHGG-UHFFFAOYSA-N 0.000 description 1
- CFUFZUWSBHTKRQ-UHFFFAOYSA-N 1-bromo-3-(2-methoxyethoxy)benzene Chemical compound COCCOC1=CC=CC(Br)=C1 CFUFZUWSBHTKRQ-UHFFFAOYSA-N 0.000 description 1
- BZYGFMKYRKQSQG-UHFFFAOYSA-N 1-bromo-3-(methoxymethyl)benzene Chemical compound COCC1=CC=CC(Br)=C1 BZYGFMKYRKQSQG-UHFFFAOYSA-N 0.000 description 1
- ZRFJYAZQMFCUIX-UHFFFAOYSA-N 1-bromo-3-ethylbenzene Chemical compound CCC1=CC=CC(Br)=C1 ZRFJYAZQMFCUIX-UHFFFAOYSA-N 0.000 description 1
- NKYFJZAKUPSUSH-UHFFFAOYSA-N 1-bromo-3-methylsulfanylbenzene Chemical compound CSC1=CC=CC(Br)=C1 NKYFJZAKUPSUSH-UHFFFAOYSA-N 0.000 description 1
- QSQOGKONVJDRNH-UHFFFAOYSA-N 1-bromo-4-iodo-2-methylbenzene Chemical compound CC1=CC(I)=CC=C1Br QSQOGKONVJDRNH-UHFFFAOYSA-N 0.000 description 1
- XTIGGAHUZJWQMD-UHFFFAOYSA-N 1-chloro-2-methoxyethane Chemical compound COCCCl XTIGGAHUZJWQMD-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- ZIXLJHSFAMVHPC-UHFFFAOYSA-N 2,3-dihydro-1-benzofuran-5-ylboronic acid Chemical compound OB(O)C1=CC=C2OCCC2=C1 ZIXLJHSFAMVHPC-UHFFFAOYSA-N 0.000 description 1
- XUDCMQBOWOLYCF-UHFFFAOYSA-N 2,3-dihydro-1h-indene-2-carboxylic acid Chemical compound C1=CC=C2CC(C(=O)O)CC2=C1 XUDCMQBOWOLYCF-UHFFFAOYSA-N 0.000 description 1
- ROZCBWIJUCJEKY-UHFFFAOYSA-N 2-(3-bromophenoxy)ethanol Chemical compound OCCOC1=CC=CC(Br)=C1 ROZCBWIJUCJEKY-UHFFFAOYSA-N 0.000 description 1
- BICJOXIWJXQQCY-UHFFFAOYSA-N 2-(3-bromophenoxy)ethoxy-tert-butyl-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)OCCOC1=CC=CC(Br)=C1 BICJOXIWJXQQCY-UHFFFAOYSA-N 0.000 description 1
- UKXUCKDFLPRYBY-UHFFFAOYSA-N 2-[4-[3-methoxy-4-(3-methoxyphenyl)phenyl]piperidin-1-yl]sulfonyl-2-methylpropanoic acid Chemical compound COC1=CC=CC(C=2C(=CC(=CC=2)C2CCN(CC2)S(=O)(=O)C(C)(C)C(O)=O)OC)=C1 UKXUCKDFLPRYBY-UHFFFAOYSA-N 0.000 description 1
- VJAWXNDERLJJSD-UHFFFAOYSA-N 2-[4-[4-(2,2-dimethyl-1,3-benzodioxol-5-yl)-3-methylphenyl]piperidin-1-yl]sulfonyl-2-methylpropanoic acid Chemical compound C=1C=C(C=2C=C3OC(C)(C)OC3=CC=2)C(C)=CC=1C1CCN(S(=O)(=O)C(C)(C)C(O)=O)CC1 VJAWXNDERLJJSD-UHFFFAOYSA-N 0.000 description 1
- BFMNPFMTIRRKNB-UHFFFAOYSA-N 2-[4-[4-(2,2-dimethyl-1,3-benzodioxol-5-yl)-3-methylphenyl]piperidin-1-yl]sulfonyl-n-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C=2C=C3OC(C)(C)OC3=CC=2)C(C)=CC=1C1CCN(S(=O)(=O)C(C)(C)C(=O)NO)CC1 BFMNPFMTIRRKNB-UHFFFAOYSA-N 0.000 description 1
- DZRBFAFYAALETF-UHFFFAOYSA-N 2-[4-[4-(3-cyanophenyl)-3-methylphenyl]piperidin-1-yl]sulfonyl-n-hydroxy-2-methylpropanamide Chemical compound CC1=CC(C2CCN(CC2)S(=O)(=O)C(C)(C)C(=O)NO)=CC=C1C1=CC=CC(C#N)=C1 DZRBFAFYAALETF-UHFFFAOYSA-N 0.000 description 1
- HAIJFZJPRSLXAD-UHFFFAOYSA-N 2-[4-[4-(3-ethoxyphenyl)-3-methoxyphenyl]piperidin-1-yl]sulfonyl-2-methylpropanoic acid Chemical compound CCOC1=CC=CC(C=2C(=CC(=CC=2)C2CCN(CC2)S(=O)(=O)C(C)(C)C(O)=O)OC)=C1 HAIJFZJPRSLXAD-UHFFFAOYSA-N 0.000 description 1
- SIMSMDREXRADNJ-UHFFFAOYSA-N 2-[4-[4-(3-ethoxyphenyl)-3-methylphenyl]piperidin-1-yl]sulfonyl-2-methylpropanoic acid Chemical compound CCOC1=CC=CC(C=2C(=CC(=CC=2)C2CCN(CC2)S(=O)(=O)C(C)(C)C(O)=O)C)=C1 SIMSMDREXRADNJ-UHFFFAOYSA-N 0.000 description 1
- XGAYXULQULBIOA-UHFFFAOYSA-N 2-[4-[4-(3-ethoxyphenyl)-3-methylphenyl]piperidin-1-yl]sulfonyl-n-hydroxyacetamide Chemical compound CCOC1=CC=CC(C=2C(=CC(=CC=2)C2CCN(CC2)S(=O)(=O)CC(=O)NO)C)=C1 XGAYXULQULBIOA-UHFFFAOYSA-N 0.000 description 1
- UCDICJCXGCXNPP-UHFFFAOYSA-N 2-[4-[4-(3-methoxyphenyl)-3-methylphenyl]piperidin-1-yl]sulfonyl-1,3-dihydroindene-2-carboxylic acid Chemical compound COC1=CC=CC(C=2C(=CC(=CC=2)C2CCN(CC2)S(=O)(=O)C2(CC3=CC=CC=C3C2)C(O)=O)C)=C1 UCDICJCXGCXNPP-UHFFFAOYSA-N 0.000 description 1
- TZBRPUIWRMHWFA-UHFFFAOYSA-N 2-[4-[4-(5-ethoxypyridin-3-yl)-3-methylphenyl]piperidin-1-yl]sulfonyl-2-methylpropanoic acid Chemical compound CCOC1=CN=CC(C=2C(=CC(=CC=2)C2CCN(CC2)S(=O)(=O)C(C)(C)C(O)=O)C)=C1 TZBRPUIWRMHWFA-UHFFFAOYSA-N 0.000 description 1
- KBAAGYUIGREQGN-UHFFFAOYSA-N 2-[4-[4-[3-(2-methoxyethoxy)phenyl]-3-methylphenyl]piperidin-1-yl]sulfonyl-2-methylpropanoic acid Chemical compound COCCOC1=CC=CC(C=2C(=CC(=CC=2)C2CCN(CC2)S(=O)(=O)C(C)(C)C(O)=O)C)=C1 KBAAGYUIGREQGN-UHFFFAOYSA-N 0.000 description 1
- QJRFEWMMQFRQAY-UHFFFAOYSA-N 2-[[4-(3-fluoro-4-phenylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]-n-hydroxyacetamide Chemical compound C1N(S(=O)(=O)CC(=O)NO)CCC(C=2C=C(F)C(=CC=2)C=2C=CC=CC=2)=C1 QJRFEWMMQFRQAY-UHFFFAOYSA-N 0.000 description 1
- NYPQSMVHDSKVCN-UHFFFAOYSA-N 2-[[4-(3-methoxy-4-phenylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]-2-methylpropanoic acid Chemical compound COC1=CC(C=2CCN(CC=2)S(=O)(=O)C(C)(C)C(O)=O)=CC=C1C1=CC=CC=C1 NYPQSMVHDSKVCN-UHFFFAOYSA-N 0.000 description 1
- RDJVRHPNTJROBJ-UHFFFAOYSA-N 2-[[4-(4-bromo-3-methylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]-2-methylpropanoic acid Chemical compound C1=C(Br)C(C)=CC(C=2CCN(CC=2)S(=O)(=O)C(C)(C)C(O)=O)=C1 RDJVRHPNTJROBJ-UHFFFAOYSA-N 0.000 description 1
- WOSPSZCZCBCJKT-UHFFFAOYSA-N 2-[[4-[4-(1,3-benzodioxol-5-yl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]-n-hydroxyacetamide Chemical compound C=1C=C(C=2C=C3OCOC3=CC=2)C(C)=CC=1C1=CCN(S(=O)(=O)CC(=O)NO)CC1 WOSPSZCZCBCJKT-UHFFFAOYSA-N 0.000 description 1
- QDHACRBTINNBHD-UHFFFAOYSA-N 2-[[4-[4-(2,3-dihydro-1-benzofuran-5-yl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]-n-hydroxyacetamide Chemical compound C=1C=C(C=2C=C3CCOC3=CC=2)C(C)=CC=1C1=CCN(S(=O)(=O)CC(=O)NO)CC1 QDHACRBTINNBHD-UHFFFAOYSA-N 0.000 description 1
- VKQGBGWRKUBOSB-UHFFFAOYSA-N 2-[[4-[4-(2,3-dihydro-1h-inden-5-yl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]-n-hydroxyacetamide Chemical compound C=1C=C(C=2C=C3CCCC3=CC=2)C(C)=CC=1C1=CCN(S(=O)(=O)CC(=O)NO)CC1 VKQGBGWRKUBOSB-UHFFFAOYSA-N 0.000 description 1
- VCCPCGSVEBHNPV-UHFFFAOYSA-N 2-[[4-[4-(2-fluorophenyl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]-n-hydroxyacetamide Chemical compound CC1=CC(C=2CCN(CC=2)S(=O)(=O)CC(=O)NO)=CC=C1C1=CC=CC=C1F VCCPCGSVEBHNPV-UHFFFAOYSA-N 0.000 description 1
- VISHEWYMDGIUDM-UHFFFAOYSA-N 2-[[4-[4-(3,4-dimethoxyphenyl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]-n-hydroxyacetamide Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=2CCN(CC=2)S(=O)(=O)CC(=O)NO)C=C1C VISHEWYMDGIUDM-UHFFFAOYSA-N 0.000 description 1
- ZYCTXGMOMNNMJI-UHFFFAOYSA-N 2-[[4-[4-(3-chloro-4-fluorophenyl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]-n-hydroxyacetamide Chemical compound CC1=CC(C=2CCN(CC=2)S(=O)(=O)CC(=O)NO)=CC=C1C1=CC=C(F)C(Cl)=C1 ZYCTXGMOMNNMJI-UHFFFAOYSA-N 0.000 description 1
- YQAAMTVEXJDZEY-UHFFFAOYSA-N 2-[[4-[4-(3-cyanophenyl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]-2-methyl-n-phenylmethoxypropanamide Chemical compound CC1=CC(C=2CCN(CC=2)S(=O)(=O)C(C)(C)C(=O)NOCC=2C=CC=CC=2)=CC=C1C1=CC=CC(C#N)=C1 YQAAMTVEXJDZEY-UHFFFAOYSA-N 0.000 description 1
- ULPHWJZHKIYQFW-UHFFFAOYSA-N 2-[[4-[4-(3-ethoxyphenyl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]-2-methylpropanoic acid Chemical compound CCOC1=CC=CC(C=2C(=CC(=CC=2)C=2CCN(CC=2)S(=O)(=O)C(C)(C)C(O)=O)C)=C1 ULPHWJZHKIYQFW-UHFFFAOYSA-N 0.000 description 1
- PNHBZAYYOGHPKN-UHFFFAOYSA-N 2-[[4-[4-(3-ethoxyphenyl)phenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]-n-hydroxyacetamide Chemical compound CCOC1=CC=CC(C=2C=CC(=CC=2)C=2CCN(CC=2)S(=O)(=O)CC(=O)NO)=C1 PNHBZAYYOGHPKN-UHFFFAOYSA-N 0.000 description 1
- LMSQNDZFBZDFQV-UHFFFAOYSA-N 2-[[4-[4-(3-ethylphenyl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]-n-hydroxyacetamide Chemical compound CCC1=CC=CC(C=2C(=CC(=CC=2)C=2CCN(CC=2)S(=O)(=O)CC(=O)NO)C)=C1 LMSQNDZFBZDFQV-UHFFFAOYSA-N 0.000 description 1
- UOYDOTUNXZKLMI-UHFFFAOYSA-N 2-bromo-6-ethoxypyridine Chemical compound CCOC1=CC=CC(Br)=N1 UOYDOTUNXZKLMI-UHFFFAOYSA-N 0.000 description 1
- REFDOIWRJDGBHY-UHFFFAOYSA-N 2-bromobenzene-1,4-diol Chemical compound OC1=CC=C(O)C(Br)=C1 REFDOIWRJDGBHY-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- VTEUIHYADULKIG-UHFFFAOYSA-N 2-ethyl-n-hydroxy-2-[[4-(4-phenylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]butanamide Chemical compound C1N(S(=O)(=O)C(CC)(C(=O)NO)CC)CCC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 VTEUIHYADULKIG-UHFFFAOYSA-N 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical class C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- USEGQJLHQSTGHW-UHFFFAOYSA-N 3-bromo-2-methylprop-1-ene Chemical compound CC(=C)CBr USEGQJLHQSTGHW-UHFFFAOYSA-N 0.000 description 1
- FYUMRYNAZSTXJV-UHFFFAOYSA-N 3-bromo-5-ethoxypyridine Chemical compound CCOC1=CN=CC(Br)=C1 FYUMRYNAZSTXJV-UHFFFAOYSA-N 0.000 description 1
- XMZQWZJMTBCUFT-UHFFFAOYSA-N 3-bromopropylbenzene Chemical compound BrCCCC1=CC=CC=C1 XMZQWZJMTBCUFT-UHFFFAOYSA-N 0.000 description 1
- UCFSYHMCKWNKAH-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CC1(C)OBOC1(C)C UCFSYHMCKWNKAH-UHFFFAOYSA-N 0.000 description 1
- SSJUBHRBJSWRFX-UHFFFAOYSA-N 4-(3-fluoro-4-phenylphenyl)-1,2,3,6-tetrahydropyridine Chemical compound FC1=CC(C=2CCNCC=2)=CC=C1C1=CC=CC=C1 SSJUBHRBJSWRFX-UHFFFAOYSA-N 0.000 description 1
- BEEJLMHFAIBSNR-UHFFFAOYSA-N 4-(3-methoxy-4-phenylphenyl)-1,2,3,6-tetrahydropyridine Chemical compound COC1=CC(C=2CCNCC=2)=CC=C1C1=CC=CC=C1 BEEJLMHFAIBSNR-UHFFFAOYSA-N 0.000 description 1
- WNKSQYFEHOAYFU-UHFFFAOYSA-N 4-(3-methyl-4-phenylphenyl)-1,2,3,6-tetrahydropyridine Chemical compound CC1=CC(C=2CCNCC=2)=CC=C1C1=CC=CC=C1 WNKSQYFEHOAYFU-UHFFFAOYSA-N 0.000 description 1
- FDRGGAPHXGEHPI-UHFFFAOYSA-N 4-(4-bromophenyl)-1,2,3,6-tetrahydropyridine Chemical compound C1=CC(Br)=CC=C1C1=CCNCC1 FDRGGAPHXGEHPI-UHFFFAOYSA-N 0.000 description 1
- MTMOLUVQNWNTBV-UHFFFAOYSA-N 4-(4-phenoxyphenyl)piperidine Chemical compound C1CNCCC1C(C=C1)=CC=C1OC1=CC=CC=C1 MTMOLUVQNWNTBV-UHFFFAOYSA-N 0.000 description 1
- NEDRMVIEJKIVCU-UHFFFAOYSA-N 4-(4-phenylphenyl)-1,2,3,6-tetrahydropyridine Chemical compound C1NCCC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 NEDRMVIEJKIVCU-UHFFFAOYSA-N 0.000 description 1
- LLCOFJXNVPRWLK-UHFFFAOYSA-N 4-(4-phenylphenyl)piperidine Chemical compound C1CNCCC1C1=CC=C(C=2C=CC=CC=2)C=C1 LLCOFJXNVPRWLK-UHFFFAOYSA-N 0.000 description 1
- AYTLTPSOUPGDOP-UHFFFAOYSA-N 4-[3-methoxy-4-(3-methoxyphenyl)phenyl]-1,2,3,6-tetrahydropyridine Chemical compound COC1=CC=CC(C=2C(=CC(=CC=2)C=2CCNCC=2)OC)=C1 AYTLTPSOUPGDOP-UHFFFAOYSA-N 0.000 description 1
- SVXJHYGFHSSGJR-UHFFFAOYSA-N 4-[4-(1,3-benzodioxol-5-yl)-3-methylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound C=1C=C(C=2C=C3OCOC3=CC=2)C(C)=CC=1C1=CCNCC1 SVXJHYGFHSSGJR-UHFFFAOYSA-N 0.000 description 1
- UUMMGLATYKNPAW-UHFFFAOYSA-N 4-[4-(2-fluorophenyl)-3-methylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound CC1=CC(C=2CCNCC=2)=CC=C1C1=CC=CC=C1F UUMMGLATYKNPAW-UHFFFAOYSA-N 0.000 description 1
- SZNIQZHJCCDNQZ-UHFFFAOYSA-N 4-[4-(3-chloro-4-fluorophenyl)-3-methylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound CC1=CC(C=2CCNCC=2)=CC=C1C1=CC=C(F)C(Cl)=C1 SZNIQZHJCCDNQZ-UHFFFAOYSA-N 0.000 description 1
- KMSCMXZTJDDGSF-UHFFFAOYSA-N 4-[4-(3-ethoxyphenyl)-3-methoxyphenyl]-1,2,3,6-tetrahydropyridine Chemical compound CCOC1=CC=CC(C=2C(=CC(=CC=2)C=2CCNCC=2)OC)=C1 KMSCMXZTJDDGSF-UHFFFAOYSA-N 0.000 description 1
- XDFJPBSVUXKORF-UHFFFAOYSA-N 4-[4-(3-methoxyphenyl)-3-methylphenyl]-1,2,3,6-tetrahydropyridine Chemical compound COC1=CC=CC(C=2C(=CC(=CC=2)C=2CCNCC=2)C)=C1 XDFJPBSVUXKORF-UHFFFAOYSA-N 0.000 description 1
- PNESJSHZQRKSQK-UHFFFAOYSA-N 4-[4-(3-methoxyphenyl)-3-methylphenyl]piperidine Chemical compound COC1=CC=CC(C=2C(=CC(=CC=2)C2CCNCC2)C)=C1 PNESJSHZQRKSQK-UHFFFAOYSA-N 0.000 description 1
- BDHDQLQZBOEDCK-UHFFFAOYSA-N 4-[4-[4-(3-ethoxyphenyl)-3-methylphenyl]piperidin-1-yl]sulfonyl-n-hydroxyoxane-4-carboxamide Chemical compound CCOC1=CC=CC(C=2C(=CC(=CC=2)C2CCN(CC2)S(=O)(=O)C2(CCOCC2)C(=O)NO)C)=C1 BDHDQLQZBOEDCK-UHFFFAOYSA-N 0.000 description 1
- UDJCKRBTDXOGNT-UHFFFAOYSA-N 4-[4-[4-(3-methoxyphenyl)-3-methylphenyl]piperidin-1-yl]sulfonyl-1-methylpiperidine-4-carboxylic acid;hydrochloride Chemical compound Cl.COC1=CC=CC(C=2C(=CC(=CC=2)C2CCN(CC2)S(=O)(=O)C2(CCN(C)CC2)C(O)=O)C)=C1 UDJCKRBTDXOGNT-UHFFFAOYSA-N 0.000 description 1
- SLXPVAJGCXFWKG-UHFFFAOYSA-N 4-[4-[4-(3-methoxyphenyl)-3-methylphenyl]piperidin-1-yl]sulfonyloxane-4-carboxylic acid Chemical compound COC1=CC=CC(C=2C(=CC(=CC=2)C2CCN(CC2)S(=O)(=O)C2(CCOCC2)C(O)=O)C)=C1 SLXPVAJGCXFWKG-UHFFFAOYSA-N 0.000 description 1
- IRHOLFFKNIBIOO-UHFFFAOYSA-N 4-[4-phenyl-3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine Chemical compound FC(F)(F)C1=CC(C=2CCNCC=2)=CC=C1C1=CC=CC=C1 IRHOLFFKNIBIOO-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- CPCDQVDNEDSEJE-UHFFFAOYSA-N 4-[[4-(4-phenylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]oxane-4-carboxylic acid Chemical compound C1CC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=CCN1S(=O)(=O)C1(C(=O)O)CCOCC1 CPCDQVDNEDSEJE-UHFFFAOYSA-N 0.000 description 1
- KZUVIWJHTCSIRZ-UHFFFAOYSA-N 4-[[4-[4-(3-ethoxyphenyl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]-n-hydroxyoxane-4-carboxamide Chemical compound CCOC1=CC=CC(C=2C(=CC(=CC=2)C=2CCN(CC=2)S(=O)(=O)C2(CCOCC2)C(=O)NO)C)=C1 KZUVIWJHTCSIRZ-UHFFFAOYSA-N 0.000 description 1
- QRPZECUMCBPTJJ-UHFFFAOYSA-N 4-[[4-[4-(3-ethoxyphenyl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]oxane-4-carboxylic acid Chemical compound CCOC1=CC=CC(C=2C(=CC(=CC=2)C=2CCN(CC=2)S(=O)(=O)C2(CCOCC2)C(O)=O)C)=C1 QRPZECUMCBPTJJ-UHFFFAOYSA-N 0.000 description 1
- ONDCQSOEGDLVGW-UHFFFAOYSA-N 4-[[4-[4-(3-methoxyphenyl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]oxane-4-carboxylic acid Chemical compound COC1=CC=CC(C=2C(=CC(=CC=2)C=2CCN(CC=2)S(=O)(=O)C2(CCOCC2)C(O)=O)C)=C1 ONDCQSOEGDLVGW-UHFFFAOYSA-N 0.000 description 1
- ZCDZFGHEIUWPFL-UHFFFAOYSA-N 4-[[4-[4-(4-ethoxyphenyl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]-n-hydroxyoxane-4-carboxamide Chemical compound C1=CC(OCC)=CC=C1C1=CC=C(C=2CCN(CC=2)S(=O)(=O)C2(CCOCC2)C(=O)NO)C=C1C ZCDZFGHEIUWPFL-UHFFFAOYSA-N 0.000 description 1
- MALRAGPAPBEFJG-UHFFFAOYSA-N 4-[[4-[4-(4-ethoxyphenyl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]oxane-4-carboxylic acid Chemical compound C1=CC(OCC)=CC=C1C1=CC=C(C=2CCN(CC=2)S(=O)(=O)C2(CCOCC2)C(O)=O)C=C1C MALRAGPAPBEFJG-UHFFFAOYSA-N 0.000 description 1
- ABGXADJDTPFFSZ-UHFFFAOYSA-N 4-benzylpiperidine Chemical compound C=1C=CC=CC=1CC1CCNCC1 ABGXADJDTPFFSZ-UHFFFAOYSA-N 0.000 description 1
- HYSCQRQMNLBEQT-UHFFFAOYSA-N 4-bromo-1-(2-fluorophenyl)-2-methylbenzene Chemical compound CC1=CC(Br)=CC=C1C1=CC=CC=C1F HYSCQRQMNLBEQT-UHFFFAOYSA-N 0.000 description 1
- VNWILWJTFRETKF-UHFFFAOYSA-N 4-bromo-1-(3-chloro-4-fluorophenyl)-2-methylbenzene Chemical compound CC1=CC(Br)=CC=C1C1=CC=C(F)C(Cl)=C1 VNWILWJTFRETKF-UHFFFAOYSA-N 0.000 description 1
- FSNATMBOYCQDHB-UHFFFAOYSA-N 4-bromo-1-(3-ethoxyphenyl)-2-methoxybenzene Chemical compound CCOC1=CC=CC(C=2C(=CC(Br)=CC=2)OC)=C1 FSNATMBOYCQDHB-UHFFFAOYSA-N 0.000 description 1
- OZULRCPDCNRQAK-UHFFFAOYSA-N 4-bromo-1-(3-methoxyphenyl)-2-methylbenzene Chemical compound COC1=CC=CC(C=2C(=CC(Br)=CC=2)C)=C1 OZULRCPDCNRQAK-UHFFFAOYSA-N 0.000 description 1
- MVDMUYIYZSWKDZ-UHFFFAOYSA-N 4-bromo-1-phenyl-2-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC(Br)=CC=C1C1=CC=CC=C1 MVDMUYIYZSWKDZ-UHFFFAOYSA-N 0.000 description 1
- PHXGKHTWEOPCEW-UHFFFAOYSA-N 4-bromo-2-(trifluoromethyl)aniline Chemical compound NC1=CC=C(Br)C=C1C(F)(F)F PHXGKHTWEOPCEW-UHFFFAOYSA-N 0.000 description 1
- YZHWZZJGCFBSPW-UHFFFAOYSA-N 4-bromo-2-methoxy-1-(3-methoxyphenyl)benzene Chemical compound COC1=CC=CC(C=2C(=CC(Br)=CC=2)OC)=C1 YZHWZZJGCFBSPW-UHFFFAOYSA-N 0.000 description 1
- ZREIJSSRWLYNDK-UHFFFAOYSA-N 4-bromo-2-methoxy-1-phenylbenzene Chemical group COC1=CC(Br)=CC=C1C1=CC=CC=C1 ZREIJSSRWLYNDK-UHFFFAOYSA-N 0.000 description 1
- VVDLSGDJJZSVMB-UHFFFAOYSA-N 4-bromo-2-methyl-1-[3-(trifluoromethyl)phenyl]benzene Chemical compound CC1=CC(Br)=CC=C1C1=CC=CC(C(F)(F)F)=C1 VVDLSGDJJZSVMB-UHFFFAOYSA-N 0.000 description 1
- ZBNARPVMXYNXQQ-UHFFFAOYSA-N 4-bromo-2-methyl-1-phenylbenzene Chemical group CC1=CC(Br)=CC=C1C1=CC=CC=C1 ZBNARPVMXYNXQQ-UHFFFAOYSA-N 0.000 description 1
- PCHYYOCUCGCSBU-UHFFFAOYSA-N 4-bromo-2-methylaniline Chemical compound CC1=CC(Br)=CC=C1N PCHYYOCUCGCSBU-UHFFFAOYSA-N 0.000 description 1
- JDUYPUMQALQRCN-UHFFFAOYSA-N 4-bromophenyl phenyl ether Chemical compound C1=CC(Br)=CC=C1OC1=CC=CC=C1 JDUYPUMQALQRCN-UHFFFAOYSA-N 0.000 description 1
- OMPXTQYWYRWWPH-UHFFFAOYSA-N 4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1NCCC(C=2C=CC=CC=2)=C1 OMPXTQYWYRWWPH-UHFFFAOYSA-N 0.000 description 1
- UTBULQCHEUWJNV-UHFFFAOYSA-N 4-phenylpiperidine Chemical compound C1CNCCC1C1=CC=CC=C1 UTBULQCHEUWJNV-UHFFFAOYSA-N 0.000 description 1
- PWJJOFDZCQDFIN-UHFFFAOYSA-N 5-(4-bromo-2-methylphenyl)-1,3-benzodioxole Chemical compound CC1=CC(Br)=CC=C1C1=CC=C(OCO2)C2=C1 PWJJOFDZCQDFIN-UHFFFAOYSA-N 0.000 description 1
- HVFQWODCWIQFFM-UHFFFAOYSA-N 5-(4-bromo-2-methylphenyl)-2,3-dihydro-1-benzofuran Chemical compound CC1=CC(Br)=CC=C1C1=CC=C(OCC2)C2=C1 HVFQWODCWIQFFM-UHFFFAOYSA-N 0.000 description 1
- KXQPLXMYJLKDMW-UHFFFAOYSA-N 5-bromo-1,2-dimethylbenzimidazole Chemical compound BrC1=CC=C2N(C)C(C)=NC2=C1 KXQPLXMYJLKDMW-UHFFFAOYSA-N 0.000 description 1
- UDWFSJAYXTXMLM-UHFFFAOYSA-N 5-bromo-2,3-dihydro-1-benzofuran Chemical compound BrC1=CC=C2OCCC2=C1 UDWFSJAYXTXMLM-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- GLBAASVPZFQEHI-UHFFFAOYSA-N COC1=C(OC)C2=C(C=C(C(OC)=C3)OC)C3=C(O)C(N(C)CC3)=C2C3=C1OC Chemical compound COC1=C(OC)C2=C(C=C(C(OC)=C3)OC)C3=C(O)C(N(C)CC3)=C2C3=C1OC GLBAASVPZFQEHI-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 208000010975 Dystrophic epidermolysis bullosa Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010022714 Intestinal ulcer Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 1
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 108010042991 NFF 2 Proteins 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- GCTFWCDSFPMHHS-UHFFFAOYSA-M Tributyltin chloride Chemical compound CCCC[Sn](Cl)(CCCC)CCCC GCTFWCDSFPMHHS-UHFFFAOYSA-M 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- PHWVCYOXHJROPI-UHFFFAOYSA-N [3-(2-methoxyethoxy)phenyl]boronic acid Chemical compound COCCOC1=CC=CC(B(O)O)=C1 PHWVCYOXHJROPI-UHFFFAOYSA-N 0.000 description 1
- XOSGESMDNPVZKS-UHFFFAOYSA-N [3-(methoxymethyl)phenyl]boronic acid Chemical compound COCC1=CC=CC(B(O)O)=C1 XOSGESMDNPVZKS-UHFFFAOYSA-N 0.000 description 1
- MXDWAYTWLXDAAB-UHFFFAOYSA-N [3-[2-[tert-butyl(diphenyl)silyl]oxyethoxy]phenyl]boronic acid Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)OCCOC1=CC=CC(B(O)O)=C1 MXDWAYTWLXDAAB-UHFFFAOYSA-N 0.000 description 1
- RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical class CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910001515 alkali metal fluoride Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
- JYZIHLWOWKMNNX-UHFFFAOYSA-N benzimidazole Chemical compound C1=C[CH]C2=NC=NC2=C1 JYZIHLWOWKMNNX-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- KMGBZBJJOKUPIA-UHFFFAOYSA-N butyl iodide Chemical compound CCCCI KMGBZBJJOKUPIA-UHFFFAOYSA-N 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 1
- 229960001701 chloroform Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- JBDSSBMEKXHSJF-UHFFFAOYSA-M cyclopentanecarboxylate Chemical compound [O-]C(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-M 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical compound C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 208000004298 epidermolysis bullosa dystrophica Diseases 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
- BAZQUXMJFOJRPA-WYMLVPIESA-N ethyl 2-[[(e)-3-(3-methoxy-4-pentoxyphenyl)prop-2-enoyl]amino]-5,6-dihydro-4h-cyclopenta[b]thiophene-3-carboxylate Chemical compound C1=C(OC)C(OCCCCC)=CC=C1\C=C\C(=O)NC1=C(C(=O)OCC)C(CCC2)=C2S1 BAZQUXMJFOJRPA-WYMLVPIESA-N 0.000 description 1
- WDCDAAMJNUHOIY-UHFFFAOYSA-N ethyl acetate;2-propan-2-yloxypropane Chemical compound CCOC(C)=O.CC(C)OC(C)C WDCDAAMJNUHOIY-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- RHMQNXNXUZLEIY-UHFFFAOYSA-N methanol;2-propan-2-yloxypropane Chemical compound OC.CC(C)OC(C)C RHMQNXNXUZLEIY-UHFFFAOYSA-N 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- LPOTVHGCLOCUJW-UHFFFAOYSA-N methyl 1-[4-[4-(3-methoxyphenyl)-3-methylphenyl]piperidin-1-yl]sulfonylcyclobutane-1-carboxylate Chemical compound C1CC(C=2C=C(C)C(=CC=2)C=2C=C(OC)C=CC=2)CCN1S(=O)(=O)C1(C(=O)OC)CCC1 LPOTVHGCLOCUJW-UHFFFAOYSA-N 0.000 description 1
- PDCBHEBNYNPQFC-UHFFFAOYSA-N methyl 2-(4-benzylpiperidin-1-yl)sulfonylacetate Chemical compound C1CN(S(=O)(=O)CC(=O)OC)CCC1CC1=CC=CC=C1 PDCBHEBNYNPQFC-UHFFFAOYSA-N 0.000 description 1
- ZTTYANWHQLJADE-UHFFFAOYSA-N methyl 2-(4-phenylpiperidin-1-yl)sulfonylacetate Chemical compound C1CN(S(=O)(=O)CC(=O)OC)CCC1C1=CC=CC=C1 ZTTYANWHQLJADE-UHFFFAOYSA-N 0.000 description 1
- DDRSXOZYELZPFK-UHFFFAOYSA-N methyl 2-[3-(4-phenylphenoxy)azetidin-1-yl]sulfonylacetate Chemical compound C1N(S(=O)(=O)CC(=O)OC)CC1OC1=CC=C(C=2C=CC=CC=2)C=C1 DDRSXOZYELZPFK-UHFFFAOYSA-N 0.000 description 1
- JFFUPAGLZSWJLZ-UHFFFAOYSA-N methyl 2-[4-(4-phenoxyphenyl)piperidin-1-yl]sulfonylacetate Chemical compound C1CN(S(=O)(=O)CC(=O)OC)CCC1C(C=C1)=CC=C1OC1=CC=CC=C1 JFFUPAGLZSWJLZ-UHFFFAOYSA-N 0.000 description 1
- FRDVAPNJXFCRET-UHFFFAOYSA-N methyl 2-[4-(4-phenylphenyl)piperidin-1-yl]sulfonylacetate Chemical compound C1CN(S(=O)(=O)CC(=O)OC)CCC1C1=CC=C(C=2C=CC=CC=2)C=C1 FRDVAPNJXFCRET-UHFFFAOYSA-N 0.000 description 1
- SCXKKUPYMLZPEB-UHFFFAOYSA-N methyl 2-[4-[3-methoxy-4-(3-methoxyphenyl)phenyl]piperidin-1-yl]sulfonyl-2-methylpropanoate Chemical compound C1CN(S(=O)(=O)C(C)(C)C(=O)OC)CCC1C1=CC=C(C=2C=C(OC)C=CC=2)C(OC)=C1 SCXKKUPYMLZPEB-UHFFFAOYSA-N 0.000 description 1
- BGSCRHKQDLDFOU-UHFFFAOYSA-N methyl 2-[4-[4-(1,2-dimethylbenzimidazol-5-yl)-3-methylphenyl]piperidin-1-yl]sulfonyl-2-methylpropanoate Chemical compound C1CN(S(=O)(=O)C(C)(C)C(=O)OC)CCC1C1=CC=C(C=2C=C3N=C(C)N(C)C3=CC=2)C(C)=C1 BGSCRHKQDLDFOU-UHFFFAOYSA-N 0.000 description 1
- JBJCKPAYNBFYQH-UHFFFAOYSA-N methyl 2-[4-[4-(2,2-dimethyl-1,3-benzodioxol-5-yl)-3-methylphenyl]piperidin-1-yl]sulfonyl-2-methylpropanoate Chemical compound C1CN(S(=O)(=O)C(C)(C)C(=O)OC)CCC1C1=CC=C(C=2C=C3OC(C)(C)OC3=CC=2)C(C)=C1 JBJCKPAYNBFYQH-UHFFFAOYSA-N 0.000 description 1
- WYIIPQAEOMWISF-UHFFFAOYSA-N methyl 2-[4-[4-(3-ethoxyphenyl)-3-methoxyphenyl]piperidin-1-yl]sulfonyl-2-methylpropanoate Chemical compound CCOC1=CC=CC(C=2C(=CC(=CC=2)C2CCN(CC2)S(=O)(=O)C(C)(C)C(=O)OC)OC)=C1 WYIIPQAEOMWISF-UHFFFAOYSA-N 0.000 description 1
- PSIJIFBJQIGRJB-UHFFFAOYSA-N methyl 2-[4-[4-(3-ethoxyphenyl)-3-methylphenyl]piperidin-1-yl]sulfonyl-2-methylpropanoate Chemical compound CCOC1=CC=CC(C=2C(=CC(=CC=2)C2CCN(CC2)S(=O)(=O)C(C)(C)C(=O)OC)C)=C1 PSIJIFBJQIGRJB-UHFFFAOYSA-N 0.000 description 1
- OUNGSSGQZWVYKT-UHFFFAOYSA-N methyl 2-[4-[4-(3-ethoxyphenyl)-3-methylphenyl]piperidin-1-yl]sulfonylacetate Chemical compound CCOC1=CC=CC(C=2C(=CC(=CC=2)C2CCN(CC2)S(=O)(=O)CC(=O)OC)C)=C1 OUNGSSGQZWVYKT-UHFFFAOYSA-N 0.000 description 1
- UPTAJYKPVUESOU-UHFFFAOYSA-N methyl 2-[4-[4-(3-methoxyphenyl)-3-methylphenyl]piperidin-1-yl]sulfonyl-1,3-dihydroindene-2-carboxylate Chemical compound C1C2=CC=CC=C2CC1(C(=O)OC)S(=O)(=O)N(CC1)CCC1C(C=C1C)=CC=C1C1=CC=CC(OC)=C1 UPTAJYKPVUESOU-UHFFFAOYSA-N 0.000 description 1
- BCIBBBAQVFPOJN-UHFFFAOYSA-N methyl 2-[4-[4-(3-methoxyphenyl)-3-methylphenyl]piperidin-1-yl]sulfonylacetate Chemical compound C1CN(S(=O)(=O)CC(=O)OC)CCC1C1=CC=C(C=2C=C(OC)C=CC=2)C(C)=C1 BCIBBBAQVFPOJN-UHFFFAOYSA-N 0.000 description 1
- PKKVHEUTNROMJA-UHFFFAOYSA-N methyl 2-[4-[4-(5-ethoxypyridin-3-yl)-3-methylphenyl]piperidin-1-yl]sulfonyl-2-methylpropanoate Chemical compound CCOC1=CN=CC(C=2C(=CC(=CC=2)C2CCN(CC2)S(=O)(=O)C(C)(C)C(=O)OC)C)=C1 PKKVHEUTNROMJA-UHFFFAOYSA-N 0.000 description 1
- KOJLVHCJQBAHBK-UHFFFAOYSA-N methyl 2-[4-[4-(6-ethoxypyridin-2-yl)-3-methylphenyl]piperidin-1-yl]sulfonyl-2-methylpropanoate Chemical compound CCOC1=CC=CC(C=2C(=CC(=CC=2)C2CCN(CC2)S(=O)(=O)C(C)(C)C(=O)OC)C)=N1 KOJLVHCJQBAHBK-UHFFFAOYSA-N 0.000 description 1
- UXAXQQPWSGYVFY-UHFFFAOYSA-N methyl 2-[4-[4-[3-(2-methoxyethoxy)phenyl]-3-methylphenyl]piperidin-1-yl]sulfonyl-2-methylpropanoate Chemical compound COCCOC1=CC=CC(C=2C(=CC(=CC=2)C2CCN(CC2)S(=O)(=O)C(C)(C)C(=O)OC)C)=C1 UXAXQQPWSGYVFY-UHFFFAOYSA-N 0.000 description 1
- OXKFWRCQJKVREC-UHFFFAOYSA-N methyl 2-[[4-(3-fluoro-4-phenylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetate Chemical compound C1N(S(=O)(=O)CC(=O)OC)CCC(C=2C=C(F)C(=CC=2)C=2C=CC=CC=2)=C1 OXKFWRCQJKVREC-UHFFFAOYSA-N 0.000 description 1
- MLDZULJDQKJPBE-UHFFFAOYSA-N methyl 2-[[4-(3-methyl-4-phenylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetate Chemical compound C1N(S(=O)(=O)CC(=O)OC)CCC(C=2C=C(C)C(=CC=2)C=2C=CC=CC=2)=C1 MLDZULJDQKJPBE-UHFFFAOYSA-N 0.000 description 1
- IXWRCTWJKLSMKK-UHFFFAOYSA-N methyl 2-[[4-(3-methyl-4-pyridin-3-ylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetate Chemical compound C1N(S(=O)(=O)CC(=O)OC)CCC(C=2C=C(C)C(=CC=2)C=2C=NC=CC=2)=C1 IXWRCTWJKLSMKK-UHFFFAOYSA-N 0.000 description 1
- UJQMIFFCPGLVKG-UHFFFAOYSA-N methyl 2-[[4-(3-methyl-4-pyridin-4-ylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetate Chemical compound C1N(S(=O)(=O)CC(=O)OC)CCC(C=2C=C(C)C(=CC=2)C=2C=CN=CC=2)=C1 UJQMIFFCPGLVKG-UHFFFAOYSA-N 0.000 description 1
- ULNZBDBDSDHGGR-UHFFFAOYSA-N methyl 2-[[4-(4-bromo-3-methylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]-2-methylpropanoate Chemical compound C1N(S(=O)(=O)C(C)(C)C(=O)OC)CCC(C=2C=C(C)C(Br)=CC=2)=C1 ULNZBDBDSDHGGR-UHFFFAOYSA-N 0.000 description 1
- YJYIHELVVMSDFL-UHFFFAOYSA-N methyl 2-[[4-(4-bromo-3-methylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetate Chemical compound C1N(S(=O)(=O)CC(=O)OC)CCC(C=2C=C(C)C(Br)=CC=2)=C1 YJYIHELVVMSDFL-UHFFFAOYSA-N 0.000 description 1
- NHLFDJMJJDUEMN-UHFFFAOYSA-N methyl 2-[[4-(4-phenylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetate Chemical compound C1N(S(=O)(=O)CC(=O)OC)CCC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 NHLFDJMJJDUEMN-UHFFFAOYSA-N 0.000 description 1
- FCMWTFDDBRVYEJ-UHFFFAOYSA-N methyl 2-[[4-[3-methoxy-4-(3-methoxyphenyl)phenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]-2-methylpropanoate Chemical compound C1N(S(=O)(=O)C(C)(C)C(=O)OC)CCC(C=2C=C(OC)C(=CC=2)C=2C=C(OC)C=CC=2)=C1 FCMWTFDDBRVYEJ-UHFFFAOYSA-N 0.000 description 1
- XZGIMYUEGPDLAR-UHFFFAOYSA-N methyl 2-[[4-[3-methoxy-4-(3-methoxyphenyl)phenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetate Chemical compound C1N(S(=O)(=O)CC(=O)OC)CCC(C=2C=C(OC)C(=CC=2)C=2C=C(OC)C=CC=2)=C1 XZGIMYUEGPDLAR-UHFFFAOYSA-N 0.000 description 1
- NVVUDBPAARZWAY-UHFFFAOYSA-N methyl 2-[[4-[3-methyl-4-[3-(trifluoromethoxy)phenyl]phenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetate Chemical compound C1N(S(=O)(=O)CC(=O)OC)CCC(C=2C=C(C)C(=CC=2)C=2C=C(OC(F)(F)F)C=CC=2)=C1 NVVUDBPAARZWAY-UHFFFAOYSA-N 0.000 description 1
- NJLYMCJOCCXEPS-UHFFFAOYSA-N methyl 2-[[4-[3-methyl-4-[3-(trifluoromethyl)phenyl]phenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetate Chemical compound C1N(S(=O)(=O)CC(=O)OC)CCC(C=2C=C(C)C(=CC=2)C=2C=C(C=CC=2)C(F)(F)F)=C1 NJLYMCJOCCXEPS-UHFFFAOYSA-N 0.000 description 1
- UOAVCEVHKRGTJK-UHFFFAOYSA-N methyl 2-[[4-[4-(1,2-dimethylbenzimidazol-5-yl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]-2-methylpropanoate Chemical compound C1N(S(=O)(=O)C(C)(C)C(=O)OC)CCC(C=2C=C(C)C(=CC=2)C=2C=C3N=C(C)N(C)C3=CC=2)=C1 UOAVCEVHKRGTJK-UHFFFAOYSA-N 0.000 description 1
- GNBAHEIHRAVMBF-UHFFFAOYSA-N methyl 2-[[4-[4-(1,3-benzodioxol-5-yl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetate Chemical compound C1N(S(=O)(=O)CC(=O)OC)CCC(C=2C=C(C)C(=CC=2)C=2C=C3OCOC3=CC=2)=C1 GNBAHEIHRAVMBF-UHFFFAOYSA-N 0.000 description 1
- QWVSYTXGCRRERG-UHFFFAOYSA-N methyl 2-[[4-[4-(2,2-dimethyl-1,3-benzodioxol-5-yl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]-2-methylpropanoate Chemical compound C1N(S(=O)(=O)C(C)(C)C(=O)OC)CCC(C=2C=C(C)C(=CC=2)C=2C=C3OC(C)(C)OC3=CC=2)=C1 QWVSYTXGCRRERG-UHFFFAOYSA-N 0.000 description 1
- PZTHQQMVPJBLEK-UHFFFAOYSA-N methyl 2-[[4-[4-(2,3-dihydro-1-benzofuran-5-yl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetate Chemical compound C1N(S(=O)(=O)CC(=O)OC)CCC(C=2C=C(C)C(=CC=2)C=2C=C3CCOC3=CC=2)=C1 PZTHQQMVPJBLEK-UHFFFAOYSA-N 0.000 description 1
- XRZPYBSTSAQVJD-UHFFFAOYSA-N methyl 2-[[4-[4-(2,3-dihydro-1h-inden-5-yl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetate Chemical compound C1N(S(=O)(=O)CC(=O)OC)CCC(C=2C=C(C)C(=CC=2)C=2C=C3CCCC3=CC=2)=C1 XRZPYBSTSAQVJD-UHFFFAOYSA-N 0.000 description 1
- WWFDJOVXEIGOIJ-UHFFFAOYSA-N methyl 2-[[4-[4-(2-fluorophenyl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetate Chemical compound C1N(S(=O)(=O)CC(=O)OC)CCC(C=2C=C(C)C(=CC=2)C=2C(=CC=CC=2)F)=C1 WWFDJOVXEIGOIJ-UHFFFAOYSA-N 0.000 description 1
- JIWPIEGHPVCNGM-UHFFFAOYSA-N methyl 2-[[4-[4-(3,4-dimethoxyphenyl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetate Chemical compound C1N(S(=O)(=O)CC(=O)OC)CCC(C=2C=C(C)C(=CC=2)C=2C=C(OC)C(OC)=CC=2)=C1 JIWPIEGHPVCNGM-UHFFFAOYSA-N 0.000 description 1
- SBNIGSRNMLWKKN-UHFFFAOYSA-N methyl 2-[[4-[4-(3-chloro-4-fluorophenyl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetate Chemical compound C1N(S(=O)(=O)CC(=O)OC)CCC(C=2C=C(C)C(=CC=2)C=2C=C(Cl)C(F)=CC=2)=C1 SBNIGSRNMLWKKN-UHFFFAOYSA-N 0.000 description 1
- GZFRWCNASIFMSZ-UHFFFAOYSA-N methyl 2-[[4-[4-(3-ethoxyphenyl)-3-methoxyphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]-2-methylpropanoate Chemical compound CCOC1=CC=CC(C=2C(=CC(=CC=2)C=2CCN(CC=2)S(=O)(=O)C(C)(C)C(=O)OC)OC)=C1 GZFRWCNASIFMSZ-UHFFFAOYSA-N 0.000 description 1
- AUYQDUDXYSVNDT-UHFFFAOYSA-N methyl 2-[[4-[4-(3-ethoxyphenyl)-3-methoxyphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetate Chemical compound CCOC1=CC=CC(C=2C(=CC(=CC=2)C=2CCN(CC=2)S(=O)(=O)CC(=O)OC)OC)=C1 AUYQDUDXYSVNDT-UHFFFAOYSA-N 0.000 description 1
- KJVPAGUHLZZYHV-UHFFFAOYSA-N methyl 2-[[4-[4-(3-ethoxyphenyl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetate Chemical compound CCOC1=CC=CC(C=2C(=CC(=CC=2)C=2CCN(CC=2)S(=O)(=O)CC(=O)OC)C)=C1 KJVPAGUHLZZYHV-UHFFFAOYSA-N 0.000 description 1
- YCURSHRSGJXMFB-UHFFFAOYSA-N methyl 2-[[4-[4-(3-ethoxyphenyl)phenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetate Chemical compound CCOC1=CC=CC(C=2C=CC(=CC=2)C=2CCN(CC=2)S(=O)(=O)CC(=O)OC)=C1 YCURSHRSGJXMFB-UHFFFAOYSA-N 0.000 description 1
- DNUPZSDNCDILNY-UHFFFAOYSA-N methyl 2-[[4-[4-(3-ethylphenyl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetate Chemical compound CCC1=CC=CC(C=2C(=CC(=CC=2)C=2CCN(CC=2)S(=O)(=O)CC(=O)OC)C)=C1 DNUPZSDNCDILNY-UHFFFAOYSA-N 0.000 description 1
- UUPGXJPULVBCJM-UHFFFAOYSA-N methyl 2-[[4-[4-(3-formylphenyl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetate Chemical compound C1N(S(=O)(=O)CC(=O)OC)CCC(C=2C=C(C)C(=CC=2)C=2C=C(C=O)C=CC=2)=C1 UUPGXJPULVBCJM-UHFFFAOYSA-N 0.000 description 1
- FIAJBKSKENNETG-UHFFFAOYSA-N methyl 2-[[4-[4-(3-methoxyphenyl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetate Chemical compound C1N(S(=O)(=O)CC(=O)OC)CCC(C=2C=C(C)C(=CC=2)C=2C=C(OC)C=CC=2)=C1 FIAJBKSKENNETG-UHFFFAOYSA-N 0.000 description 1
- KAYSTOBLMMSJIW-UHFFFAOYSA-N methyl 2-[[4-[4-(5-ethoxypyridin-3-yl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]-2-methylpropanoate Chemical compound CCOC1=CN=CC(C=2C(=CC(=CC=2)C=2CCN(CC=2)S(=O)(=O)C(C)(C)C(=O)OC)C)=C1 KAYSTOBLMMSJIW-UHFFFAOYSA-N 0.000 description 1
- WPCPVHRMYNUKOB-UHFFFAOYSA-N methyl 2-[[4-[4-(6-ethoxypyridin-2-yl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]-2-methylpropanoate Chemical compound CCOC1=CC=CC(C=2C(=CC(=CC=2)C=2CCN(CC=2)S(=O)(=O)C(C)(C)C(=O)OC)C)=N1 WPCPVHRMYNUKOB-UHFFFAOYSA-N 0.000 description 1
- SDXLBFLEBCMMSO-UHFFFAOYSA-N methyl 2-[[4-[4-[3-(2-methoxyethoxy)phenyl]-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]-2-methylpropanoate Chemical compound COCCOC1=CC=CC(C=2C(=CC(=CC=2)C=2CCN(CC=2)S(=O)(=O)C(C)(C)C(=O)OC)C)=C1 SDXLBFLEBCMMSO-UHFFFAOYSA-N 0.000 description 1
- KVUPLHYJILUZBM-UHFFFAOYSA-N methyl 2-[[4-[4-[3-(hydroxymethyl)phenyl]-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetate Chemical compound C1N(S(=O)(=O)CC(=O)OC)CCC(C=2C=C(C)C(=CC=2)C=2C=C(CO)C=CC=2)=C1 KVUPLHYJILUZBM-UHFFFAOYSA-N 0.000 description 1
- IBCBRQIGZHDKSP-UHFFFAOYSA-N methyl 2-[[4-[4-[3-(methoxymethyl)phenyl]-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetate Chemical compound COCC1=CC=CC(C=2C(=CC(=CC=2)C=2CCN(CC=2)S(=O)(=O)CC(=O)OC)C)=C1 IBCBRQIGZHDKSP-UHFFFAOYSA-N 0.000 description 1
- CXMWZLRRELTEGW-UHFFFAOYSA-N methyl 2-[[4-[4-phenyl-3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetate Chemical compound C1N(S(=O)(=O)CC(=O)OC)CCC(C=2C=C(C(C=3C=CC=CC=3)=CC=2)C(F)(F)F)=C1 CXMWZLRRELTEGW-UHFFFAOYSA-N 0.000 description 1
- ZFSLJVTWAJXSLK-UHFFFAOYSA-N methyl 4-[4-[4-(3-methoxyphenyl)-3-methylphenyl]piperidin-1-yl]sulfonyl-1-methylpiperidine-4-carboxylate Chemical compound C1CC(C=2C=C(C)C(=CC=2)C=2C=C(OC)C=CC=2)CCN1S(=O)(=O)C1(C(=O)OC)CCN(C)CC1 ZFSLJVTWAJXSLK-UHFFFAOYSA-N 0.000 description 1
- WOMOLSSVAJRPEA-UHFFFAOYSA-N methyl 4-[4-[4-(3-methoxyphenyl)-3-methylphenyl]piperidin-1-yl]sulfonyloxane-4-carboxylate Chemical compound C1CC(C=2C=C(C)C(=CC=2)C=2C=C(OC)C=CC=2)CCN1S(=O)(=O)C1(C(=O)OC)CCOCC1 WOMOLSSVAJRPEA-UHFFFAOYSA-N 0.000 description 1
- TXSWIMGHLUHJFE-UHFFFAOYSA-N methyl 4-[[4-(4-phenylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]oxane-4-carboxylate Chemical compound C1CC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=CCN1S(=O)(=O)C1(C(=O)OC)CCOCC1 TXSWIMGHLUHJFE-UHFFFAOYSA-N 0.000 description 1
- QAMVFTZOSRZROU-UHFFFAOYSA-N methyl 4-[[4-[4-(3-ethoxyphenyl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]oxane-4-carboxylate Chemical compound CCOC1=CC=CC(C=2C(=CC(=CC=2)C=2CCN(CC=2)S(=O)(=O)C2(CCOCC2)C(=O)OC)C)=C1 QAMVFTZOSRZROU-UHFFFAOYSA-N 0.000 description 1
- FPFCCMXJTSSQHG-UHFFFAOYSA-N methyl 4-[[4-[4-(3-methoxyphenyl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]oxane-4-carboxylate Chemical compound C1CC(C=2C=C(C)C(=CC=2)C=2C=C(OC)C=CC=2)=CCN1S(=O)(=O)C1(C(=O)OC)CCOCC1 FPFCCMXJTSSQHG-UHFFFAOYSA-N 0.000 description 1
- WIQSGJXPICEZLP-UHFFFAOYSA-N methyl 4-[[4-[4-(4-ethoxyphenyl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]oxane-4-carboxylate Chemical compound C1=CC(OCC)=CC=C1C1=CC=C(C=2CCN(CC=2)S(=O)(=O)C2(CCOCC2)C(=O)OC)C=C1C WIQSGJXPICEZLP-UHFFFAOYSA-N 0.000 description 1
- VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- HQCBGSCOEUKQGA-UHFFFAOYSA-N n-[2-(2-fluorophenyl)ethyl]-3-(4-methyl-1,1,3-trioxo-1,2-thiazolidin-2-yl)benzamide Chemical compound O=C1C(C)CS(=O)(=O)N1C1=CC=CC(C(=O)NCCC=2C(=CC=CC=2)F)=C1 HQCBGSCOEUKQGA-UHFFFAOYSA-N 0.000 description 1
- XYXNUAHTTLZWPA-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-2-[3-oxo-6-(trifluoromethyl)-4h-1,4-benzothiazin-2-yl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC(=O)CC1C(=O)NC2=CC(C(F)(F)F)=CC=C2S1 XYXNUAHTTLZWPA-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- RIVIDPPYRINTTH-UHFFFAOYSA-N n-ethylpropan-2-amine Chemical compound CCNC(C)C RIVIDPPYRINTTH-UHFFFAOYSA-N 0.000 description 1
- KKTSHMVWIWIUCV-UHFFFAOYSA-N n-hydroxy-1-[[4-(3-methyl-4-phenylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]cyclopentane-1-carboxamide Chemical compound CC1=CC(C=2CCN(CC=2)S(=O)(=O)C2(CCCC2)C(=O)NO)=CC=C1C1=CC=CC=C1 KKTSHMVWIWIUCV-UHFFFAOYSA-N 0.000 description 1
- DZKBXUUQLMNCGH-UHFFFAOYSA-N n-hydroxy-2-(4-phenylpiperidin-1-yl)sulfonylacetamide Chemical compound C1CN(S(=O)(=O)CC(=O)NO)CCC1C1=CC=CC=C1 DZKBXUUQLMNCGH-UHFFFAOYSA-N 0.000 description 1
- DORBNZHQHOCIEP-UHFFFAOYSA-N n-hydroxy-2-[(4-phenyl-3,6-dihydro-2h-pyridin-1-yl)sulfonyl]acetamide Chemical compound C1N(S(=O)(=O)CC(=O)NO)CCC(C=2C=CC=CC=2)=C1 DORBNZHQHOCIEP-UHFFFAOYSA-N 0.000 description 1
- RNRPMRLNLCZHAR-UHFFFAOYSA-N n-hydroxy-2-[3-(4-phenylphenoxy)azetidin-1-yl]sulfonylacetamide Chemical compound C1N(S(=O)(=O)CC(=O)NO)CC1OC1=CC=C(C=2C=CC=CC=2)C=C1 RNRPMRLNLCZHAR-UHFFFAOYSA-N 0.000 description 1
- WKVUGFBWMFZOMW-UHFFFAOYSA-N n-hydroxy-2-[4-(4-phenoxyphenyl)piperidin-1-yl]sulfonylacetamide Chemical compound C1CN(S(=O)(=O)CC(=O)NO)CCC1C(C=C1)=CC=C1OC1=CC=CC=C1 WKVUGFBWMFZOMW-UHFFFAOYSA-N 0.000 description 1
- OAQPUVCDKMAGGE-UHFFFAOYSA-N n-hydroxy-2-[4-(4-phenylphenyl)piperidin-1-yl]sulfonylacetamide Chemical compound C1CN(S(=O)(=O)CC(=O)NO)CCC1C1=CC=C(C=2C=CC=CC=2)C=C1 OAQPUVCDKMAGGE-UHFFFAOYSA-N 0.000 description 1
- MKBKQKMSVPLPFO-UHFFFAOYSA-N n-hydroxy-2-[4-[3-methoxy-4-(3-methoxyphenyl)phenyl]piperidin-1-yl]sulfonyl-2-methylpropanamide Chemical compound COC1=CC=CC(C=2C(=CC(=CC=2)C2CCN(CC2)S(=O)(=O)C(C)(C)C(=O)NO)OC)=C1 MKBKQKMSVPLPFO-UHFFFAOYSA-N 0.000 description 1
- STTXOLDYEVPGIB-UHFFFAOYSA-N n-hydroxy-2-[4-[4-(3-methoxyphenyl)-3-methylphenyl]piperidin-1-yl]sulfonyl-1,3-dihydroindene-2-carboxamide Chemical compound COC1=CC=CC(C=2C(=CC(=CC=2)C2CCN(CC2)S(=O)(=O)C2(CC3=CC=CC=C3C2)C(=O)NO)C)=C1 STTXOLDYEVPGIB-UHFFFAOYSA-N 0.000 description 1
- RBHHIGVLNBWSPZ-UHFFFAOYSA-N n-hydroxy-2-[[4-(3-methoxy-4-phenylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]-2-methylpropanamide Chemical compound COC1=CC(C=2CCN(CC=2)S(=O)(=O)C(C)(C)C(=O)NO)=CC=C1C1=CC=CC=C1 RBHHIGVLNBWSPZ-UHFFFAOYSA-N 0.000 description 1
- PERLYMNYNGIFQO-UHFFFAOYSA-N n-hydroxy-2-[[4-(3-methoxy-4-phenylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetamide Chemical compound COC1=CC(C=2CCN(CC=2)S(=O)(=O)CC(=O)NO)=CC=C1C1=CC=CC=C1 PERLYMNYNGIFQO-UHFFFAOYSA-N 0.000 description 1
- OWAPDZZCMRGQHC-UHFFFAOYSA-N n-hydroxy-2-[[4-(3-methyl-4-phenylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetamide Chemical compound CC1=CC(C=2CCN(CC=2)S(=O)(=O)CC(=O)NO)=CC=C1C1=CC=CC=C1 OWAPDZZCMRGQHC-UHFFFAOYSA-N 0.000 description 1
- GCWPZNBDJVBKIN-UHFFFAOYSA-N n-hydroxy-2-[[4-(3-methyl-4-phenylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]pent-4-enamide Chemical compound CC1=CC(C=2CCN(CC=2)S(=O)(=O)C(CC=C)C(=O)NO)=CC=C1C1=CC=CC=C1 GCWPZNBDJVBKIN-UHFFFAOYSA-N 0.000 description 1
- OOFYDTUVBWVYBW-UHFFFAOYSA-N n-hydroxy-2-[[4-(3-methyl-4-pyridin-3-ylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetamide Chemical compound CC1=CC(C=2CCN(CC=2)S(=O)(=O)CC(=O)NO)=CC=C1C1=CC=CN=C1 OOFYDTUVBWVYBW-UHFFFAOYSA-N 0.000 description 1
- IHFFZTJTRHPWSC-UHFFFAOYSA-N n-hydroxy-2-[[4-(4-phenylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]-1,3-dihydroindene-2-carboxamide Chemical compound C1C2=CC=CC=C2CC1(C(=O)NO)S(=O)(=O)N(CC=1)CCC=1C(C=C1)=CC=C1C1=CC=CC=C1 IHFFZTJTRHPWSC-UHFFFAOYSA-N 0.000 description 1
- GYHDAVSEPKRYGB-UHFFFAOYSA-N n-hydroxy-2-[[4-(4-phenylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetamide Chemical compound C1N(S(=O)(=O)CC(=O)NO)CCC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 GYHDAVSEPKRYGB-UHFFFAOYSA-N 0.000 description 1
- RIJWZUOAXQJQKW-UHFFFAOYSA-N n-hydroxy-2-[[4-(4-phenylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]hexanamide Chemical compound C1N(S(=O)(=O)C(C(=O)NO)CCCC)CCC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 RIJWZUOAXQJQKW-UHFFFAOYSA-N 0.000 description 1
- WWNOVBOBOQYKQC-UHFFFAOYSA-N n-hydroxy-2-[[4-(4-phenylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]pent-4-enamide Chemical compound C1N(S(=O)(=O)C(CC=C)C(=O)NO)CCC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 WWNOVBOBOQYKQC-UHFFFAOYSA-N 0.000 description 1
- XYWAHCZIHPNBSK-UHFFFAOYSA-N n-hydroxy-2-[[4-[3-methyl-4-(3-methylsulfanylphenyl)phenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetamide Chemical compound CSC1=CC=CC(C=2C(=CC(=CC=2)C=2CCN(CC=2)S(=O)(=O)CC(=O)NO)C)=C1 XYWAHCZIHPNBSK-UHFFFAOYSA-N 0.000 description 1
- GIXYBRZLOBPOLX-UHFFFAOYSA-N n-hydroxy-2-[[4-[3-methyl-4-[3-(trifluoromethoxy)phenyl]phenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetamide Chemical compound CC1=CC(C=2CCN(CC=2)S(=O)(=O)CC(=O)NO)=CC=C1C1=CC=CC(OC(F)(F)F)=C1 GIXYBRZLOBPOLX-UHFFFAOYSA-N 0.000 description 1
- XUIFTRYKPATNMO-UHFFFAOYSA-N n-hydroxy-2-[[4-[3-methyl-4-[3-(trifluoromethyl)phenyl]phenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetamide Chemical compound CC1=CC(C=2CCN(CC=2)S(=O)(=O)CC(=O)NO)=CC=C1C1=CC=CC(C(F)(F)F)=C1 XUIFTRYKPATNMO-UHFFFAOYSA-N 0.000 description 1
- AFLLOSXTZXYSAK-UHFFFAOYSA-N n-hydroxy-2-[[4-[4-(3-methoxyphenyl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetamide Chemical compound COC1=CC=CC(C=2C(=CC(=CC=2)C=2CCN(CC=2)S(=O)(=O)CC(=O)NO)C)=C1 AFLLOSXTZXYSAK-UHFFFAOYSA-N 0.000 description 1
- XWTCJMPDJYMPCX-UHFFFAOYSA-N n-hydroxy-2-[[4-[4-[3-(2-methoxyethoxy)phenyl]-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetamide Chemical compound COCCOC1=CC=CC(C=2C(=CC(=CC=2)C=2CCN(CC=2)S(=O)(=O)CC(=O)NO)C)=C1 XWTCJMPDJYMPCX-UHFFFAOYSA-N 0.000 description 1
- CFYFSLBEBAHWIH-UHFFFAOYSA-N n-hydroxy-2-[[4-[4-[3-(hydroxymethyl)phenyl]-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetamide Chemical compound CC1=CC(C=2CCN(CC=2)S(=O)(=O)CC(=O)NO)=CC=C1C1=CC=CC(CO)=C1 CFYFSLBEBAHWIH-UHFFFAOYSA-N 0.000 description 1
- SKUFTRBSRXIMDB-UHFFFAOYSA-N n-hydroxy-2-[[4-[4-[3-(methoxymethyl)phenyl]-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetamide Chemical compound COCC1=CC=CC(C=2C(=CC(=CC=2)C=2CCN(CC=2)S(=O)(=O)CC(=O)NO)C)=C1 SKUFTRBSRXIMDB-UHFFFAOYSA-N 0.000 description 1
- URSVZCYOMZVHJE-UHFFFAOYSA-N n-hydroxy-2-[[4-[4-phenyl-3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]acetamide Chemical compound C1N(S(=O)(=O)CC(=O)NO)CCC(C=2C=C(C(C=3C=CC=CC=3)=CC=2)C(F)(F)F)=C1 URSVZCYOMZVHJE-UHFFFAOYSA-N 0.000 description 1
- AMIIJAZCPPVSGL-UHFFFAOYSA-N n-hydroxy-2-methyl-2-[[4-(3-methyl-4-phenylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]pent-4-enamide Chemical compound CC1=CC(C=2CCN(CC=2)S(=O)(=O)C(C)(CC=C)C(=O)NO)=CC=C1C1=CC=CC=C1 AMIIJAZCPPVSGL-UHFFFAOYSA-N 0.000 description 1
- NIUTWRHILKIPOQ-UHFFFAOYSA-N n-hydroxy-2-methyl-2-[[4-(3-methyl-4-quinolin-3-ylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]propanamide Chemical compound C=1C=C(C=2C=C3C=CC=CC3=NC=2)C(C)=CC=1C1=CCN(S(=O)(=O)C(C)(C)C(=O)NO)CC1 NIUTWRHILKIPOQ-UHFFFAOYSA-N 0.000 description 1
- IAKULKQFRWIOFB-UHFFFAOYSA-N n-hydroxy-2-methyl-2-[[4-(4-phenylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]propanamide Chemical compound C1N(S(=O)(=O)C(C)(C(=O)NO)C)CCC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 IAKULKQFRWIOFB-UHFFFAOYSA-N 0.000 description 1
- POSBOCFAWZGTSL-UHFFFAOYSA-N n-hydroxy-2-sulfamoylacetamide Chemical class NS(=O)(=O)CC(=O)NO POSBOCFAWZGTSL-UHFFFAOYSA-N 0.000 description 1
- AYMHCNJJHGDUAG-UHFFFAOYSA-N n-hydroxy-3-phenyl-2-[[4-(4-phenylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]propanamide Chemical compound C1CC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=CCN1S(=O)(=O)C(C(=O)NO)CC1=CC=CC=C1 AYMHCNJJHGDUAG-UHFFFAOYSA-N 0.000 description 1
- DKAYSZVMUKGYFV-UHFFFAOYSA-N n-hydroxy-4-[4-[4-(3-methoxyphenyl)-3-methylphenyl]piperidin-1-yl]sulfonyloxane-4-carboxamide Chemical compound COC1=CC=CC(C=2C(=CC(=CC=2)C2CCN(CC2)S(=O)(=O)C2(CCOCC2)C(=O)NO)C)=C1 DKAYSZVMUKGYFV-UHFFFAOYSA-N 0.000 description 1
- MFBWMFLIOKGEAA-UHFFFAOYSA-N n-hydroxy-4-[[4-(3-methyl-4-phenylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]oxane-4-carboxamide Chemical compound CC1=CC(C=2CCN(CC=2)S(=O)(=O)C2(CCOCC2)C(=O)NO)=CC=C1C1=CC=CC=C1 MFBWMFLIOKGEAA-UHFFFAOYSA-N 0.000 description 1
- SHEPFAHPUSXOCH-UHFFFAOYSA-N n-hydroxy-4-[[4-(4-phenylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]oxane-4-carboxamide Chemical compound C1CC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=CCN1S(=O)(=O)C1(C(=O)NO)CCOCC1 SHEPFAHPUSXOCH-UHFFFAOYSA-N 0.000 description 1
- IAPYBXNKWSWINJ-UHFFFAOYSA-N n-hydroxy-4-[[4-[4-(3-methoxyphenyl)-3-methylphenyl]-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]oxane-4-carboxamide Chemical compound COC1=CC=CC(C=2C(=CC(=CC=2)C=2CCN(CC=2)S(=O)(=O)C2(CCOCC2)C(=O)NO)C)=C1 IAPYBXNKWSWINJ-UHFFFAOYSA-N 0.000 description 1
- ZFQCZUSHTBRBQV-UHFFFAOYSA-N n-hydroxy-4-methoxy-2-[[4-(3-methyl-4-phenylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]butanamide Chemical compound C1N(S(=O)(=O)C(C(=O)NO)CCOC)CCC(C=2C=C(C)C(=CC=2)C=2C=CC=CC=2)=C1 ZFQCZUSHTBRBQV-UHFFFAOYSA-N 0.000 description 1
- YYNGVTLAXROTOG-UHFFFAOYSA-N n-hydroxy-4-methyl-2-[[4-(4-phenylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]pent-4-enamide Chemical compound C1N(S(=O)(=O)C(C(=O)NO)CC(=C)C)CCC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 YYNGVTLAXROTOG-UHFFFAOYSA-N 0.000 description 1
- KQAUKILYRDJVMU-UHFFFAOYSA-N n-hydroxy-5-phenyl-2-[[4-(4-phenylphenyl)-3,6-dihydro-2h-pyridin-1-yl]sulfonyl]pentanamide Chemical compound C1CC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=CCN1S(=O)(=O)C(C(=O)NO)CCCC1=CC=CC=C1 KQAUKILYRDJVMU-UHFFFAOYSA-N 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- AVPKHOTUOHDTLW-UHFFFAOYSA-N oxane-4-carboxylic acid Chemical compound OC(=O)C1CCOCC1 AVPKHOTUOHDTLW-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- HXOFRBVHQQOXNL-UHFFFAOYSA-N phenyl(trifluoromethoxy)borinic acid Chemical compound FC(F)(F)OB(O)C1=CC=CC=C1 HXOFRBVHQQOXNL-UHFFFAOYSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- IHKUAFRJHFOVKI-UHFFFAOYSA-N tert-butyl 4-(3-fluoro-4-phenylphenyl)-4-hydroxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1(O)C1=CC=C(C=2C=CC=CC=2)C(F)=C1 IHKUAFRJHFOVKI-UHFFFAOYSA-N 0.000 description 1
- YYUQXWONPLPBBA-UHFFFAOYSA-N tert-butyl 4-(4-bromo-3-methylphenyl)-4-hydroxypiperidine-1-carboxylate Chemical compound C1=C(Br)C(C)=CC(C2(O)CCN(CC2)C(=O)OC(C)(C)C)=C1 YYUQXWONPLPBBA-UHFFFAOYSA-N 0.000 description 1
- ZXVYIHCSSJUVBB-UHFFFAOYSA-N tert-butyl 4-(4-bromophenyl)-4-hydroxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1(O)C1=CC=C(Br)C=C1 ZXVYIHCSSJUVBB-UHFFFAOYSA-N 0.000 description 1
- ADOCBRWVVNDMGQ-UHFFFAOYSA-N tert-butyl 4-[4-(1,3-benzodioxol-5-yl)-3-methylphenyl]-4-hydroxypiperidine-1-carboxylate Chemical compound C=1C=C(C=2C=C3OCOC3=CC=2)C(C)=CC=1C1(O)CCN(C(=O)OC(C)(C)C)CC1 ADOCBRWVVNDMGQ-UHFFFAOYSA-N 0.000 description 1
- COEIEMBOFOKSBM-UHFFFAOYSA-N tert-butyl 4-[4-(2-fluorophenyl)-3-methylphenyl]-4-hydroxypiperidine-1-carboxylate Chemical compound CC1=CC(C2(O)CCN(CC2)C(=O)OC(C)(C)C)=CC=C1C1=CC=CC=C1F COEIEMBOFOKSBM-UHFFFAOYSA-N 0.000 description 1
- DVQBDFUJNMOOQB-UHFFFAOYSA-N tert-butyl 4-[4-(3-chloro-4-fluorophenyl)-3-methylphenyl]-4-hydroxypiperidine-1-carboxylate Chemical compound CC1=CC(C2(O)CCN(CC2)C(=O)OC(C)(C)C)=CC=C1C1=CC=C(F)C(Cl)=C1 DVQBDFUJNMOOQB-UHFFFAOYSA-N 0.000 description 1
- WFJRDHSQDHGIIL-UHFFFAOYSA-N tert-butyl 4-hydroxy-4-(3-methoxy-4-phenylphenyl)piperidine-1-carboxylate Chemical compound COC1=CC(C2(O)CCN(CC2)C(=O)OC(C)(C)C)=CC=C1C1=CC=CC=C1 WFJRDHSQDHGIIL-UHFFFAOYSA-N 0.000 description 1
- PAATUKWJCVNHCM-UHFFFAOYSA-N tert-butyl 4-hydroxy-4-(3-methyl-4-phenylphenyl)piperidine-1-carboxylate Chemical compound CC1=CC(C2(O)CCN(CC2)C(=O)OC(C)(C)C)=CC=C1C1=CC=CC=C1 PAATUKWJCVNHCM-UHFFFAOYSA-N 0.000 description 1
- YYFGIOHMKFTSEK-UHFFFAOYSA-N tert-butyl 4-hydroxy-4-(4-phenoxyphenyl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1(O)C(C=C1)=CC=C1OC1=CC=CC=C1 YYFGIOHMKFTSEK-UHFFFAOYSA-N 0.000 description 1
- SZCYKXFOZZBPCU-UHFFFAOYSA-N tert-butyl 4-hydroxy-4-(4-phenylphenyl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1(O)C1=CC=C(C=2C=CC=CC=2)C=C1 SZCYKXFOZZBPCU-UHFFFAOYSA-N 0.000 description 1
- JONZESLINMAWGI-UHFFFAOYSA-N tert-butyl 4-hydroxy-4-[4-phenyl-3-(trifluoromethyl)phenyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1(O)C(C=C1C(F)(F)F)=CC=C1C1=CC=CC=C1 JONZESLINMAWGI-UHFFFAOYSA-N 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000009901 transfer hydrogenation reaction Methods 0.000 description 1
- GYUURHMITDQTRU-UHFFFAOYSA-N tributyl(pyridin-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=CC=N1 GYUURHMITDQTRU-UHFFFAOYSA-N 0.000 description 1
- CFQJBWKKHCMCGJ-UHFFFAOYSA-N tributyl(pyridin-3-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=CN=C1 CFQJBWKKHCMCGJ-UHFFFAOYSA-N 0.000 description 1
- UNEPXPMBVGDXGH-UHFFFAOYSA-N tributyl(pyridin-4-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=NC=C1 UNEPXPMBVGDXGH-UHFFFAOYSA-N 0.000 description 1
- FDNMDFMLMDHWRX-UHFFFAOYSA-N tributyl-(5-ethoxypyridin-3-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CN=CC(OCC)=C1 FDNMDFMLMDHWRX-UHFFFAOYSA-N 0.000 description 1
- IDMFTWUNPWQGQT-UHFFFAOYSA-N tributyl-(6-ethoxypyridin-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=CC(OCC)=N1 IDMFTWUNPWQGQT-UHFFFAOYSA-N 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9725782.8A GB9725782D0 (en) | 1997-12-05 | 1997-12-05 | Therapeutic agents |
PCT/EP1998/006640 WO1999029667A1 (en) | 1997-12-05 | 1998-10-09 | Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20000373A2 true HRP20000373A2 (en) | 2000-12-31 |
Family
ID=10823173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20000373A HRP20000373A2 (en) | 1997-12-05 | 2000-06-05 | Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors |
Country Status (41)
Country | Link |
---|---|
US (1) | US6495568B1 (uk) |
EP (1) | EP1036062B1 (uk) |
JP (1) | JP3445242B2 (uk) |
KR (1) | KR100372990B1 (uk) |
CN (1) | CN1281433A (uk) |
AP (1) | AP930A (uk) |
AR (1) | AR016429A1 (uk) |
AT (1) | ATE257151T1 (uk) |
AU (1) | AU741859B2 (uk) |
BG (1) | BG104506A (uk) |
BR (1) | BR9813360A (uk) |
CA (1) | CA2312935C (uk) |
CZ (1) | CZ20002037A3 (uk) |
DE (1) | DE69820906T2 (uk) |
DK (1) | DK1036062T3 (uk) |
DZ (1) | DZ2666A1 (uk) |
EA (1) | EA002882B1 (uk) |
ES (1) | ES2212373T3 (uk) |
GB (1) | GB9725782D0 (uk) |
GT (1) | GT199800189A (uk) |
HR (1) | HRP20000373A2 (uk) |
HU (1) | HUP0100845A3 (uk) |
ID (1) | ID24626A (uk) |
IL (1) | IL136300A0 (uk) |
IS (1) | IS5503A (uk) |
MA (1) | MA26571A1 (uk) |
NO (1) | NO20002826L (uk) |
NZ (1) | NZ504421A (uk) |
OA (1) | OA11388A (uk) |
PA (1) | PA8463501A1 (uk) |
PE (1) | PE133999A1 (uk) |
PL (1) | PL341031A1 (uk) |
PT (1) | PT1036062E (uk) |
SK (1) | SK7822000A3 (uk) |
TN (1) | TNSN98216A1 (uk) |
TR (1) | TR200001611T2 (uk) |
UA (1) | UA52791C2 (uk) |
UY (2) | UY25282A1 (uk) |
WO (1) | WO1999029667A1 (uk) |
YU (1) | YU32100A (uk) |
ZA (1) | ZA9811112B (uk) |
Families Citing this family (289)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9801690D0 (en) * | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
TR200002225T2 (tr) * | 1998-01-28 | 2000-12-21 | Shionogi & Co., Ltd | Yeni trisiklik bileşimler |
EP1157021A1 (en) | 1999-02-08 | 2001-11-28 | G.D. SEARLE & CO. | Sulfamato hydroxamic acid metalloprotease inhibitor |
US6800646B1 (en) | 1999-02-08 | 2004-10-05 | Pharmacia Corporation | Sulfamato hydroxamic acid metalloprotease inhibitor |
GB9912961D0 (en) * | 1999-06-03 | 1999-08-04 | Pfizer Ltd | Metalloprotease inhibitors |
US6511993B1 (en) * | 1999-06-03 | 2003-01-28 | Kevin Neil Dack | Metalloprotease inhibitors |
UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
EP1261595A1 (en) * | 2000-02-21 | 2002-12-04 | AstraZeneca AB | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents |
JO2409B1 (en) | 2000-11-21 | 2007-06-17 | شركة جانسين فارماسوتيكا ان. في | Second-phenyl carboxy amides are useful as lipid-lowering agents |
MX349009B (es) | 2001-01-05 | 2017-07-06 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina. |
GB0108102D0 (en) * | 2001-03-30 | 2001-05-23 | Pfizer Ltd | Compounds |
US6821972B2 (en) | 2001-03-30 | 2004-11-23 | Pfizer Inc. | 3-heterocyclylpropanohydroxamic acid PCP inhibitors |
AU2002345792A1 (en) | 2001-06-21 | 2003-01-08 | Pfizer Inc. | Thienopyridine and thienopyrimidine anticancer agents |
GB0119474D0 (en) | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
JP2005516927A (ja) * | 2001-12-13 | 2005-06-09 | アボット・ラボラトリーズ | 癌治療用のキナーゼ阻害剤としての3−(フェニル−アルコキシ)−5−(フェニル)−ピリジン誘導体および関連化合物 |
PL233493B1 (pl) | 2002-03-13 | 2019-10-31 | Array Biopharma Inc | Związek benzoimidazolowy, jego zastosowanie oraz zawierająca go kompozycja farmaceutyczna |
US20050209278A1 (en) * | 2002-04-25 | 2005-09-22 | Mcdonald Joseph J | Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
AU2003221786A1 (en) * | 2002-04-25 | 2003-11-10 | Pharmacia Corporation | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
UA77303C2 (en) | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
JP2006502980A (ja) * | 2002-06-25 | 2006-01-26 | ファルマシア・コーポレーション | アリールスルホニルヒドロキサム酸およびアミド誘導体、ならびにプロテアーゼ阻害薬としてのそれらの使用 |
AU2003300800A1 (en) * | 2002-11-25 | 2004-06-18 | Pharmacia Corporation | Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors |
ES2524803T3 (es) | 2002-12-19 | 2014-12-12 | The Scripps Research Institute | Composiciones y métodos para estabilizar la transtiretina e inhibir el plegamiento anómalo de la transtiretina |
BR0317548A (pt) | 2002-12-19 | 2005-11-22 | Pfizer | Compostos de indazole e composições farmacêuticas para a inibição de proteìnas-cinases e métodos para o seu uso |
WO2004060346A2 (en) | 2002-12-30 | 2004-07-22 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
DK2476667T3 (da) | 2003-02-26 | 2014-09-15 | Sugen Inc | Aminoheteroaryl-forbindelser som proteinkinase-inhibitorer |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
SI1682138T1 (sl) | 2003-11-19 | 2011-04-29 | Array Biopharma Inc | HETEROCIKLIÄŚNI INHIBITORJI MEK-a |
AU2005245470A1 (en) * | 2004-05-20 | 2005-12-01 | Foldrx Pharmaceuticals, Inc. | 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
UA87153C2 (uk) | 2004-08-26 | 2009-06-25 | Пфайзер Инк. | Енантіомерно чисті аміногетероарильні сполуки як інгібітори протеїнкінази |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
US7429667B2 (en) | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
AU2006299902B2 (en) | 2005-05-18 | 2012-11-01 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7897624B2 (en) | 2006-04-18 | 2011-03-01 | Ardea Biosciences | Pyridone sulfonamides and pyridone sulfamides as MEK inhibitors |
US8101799B2 (en) | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
WO2007016525A2 (en) | 2005-07-29 | 2007-02-08 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
CA2623125A1 (en) | 2005-09-20 | 2007-03-29 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
TWI405756B (zh) | 2005-12-21 | 2013-08-21 | Array Biopharma Inc | 新穎硫酸氫鹽 |
WO2007121269A2 (en) | 2006-04-11 | 2007-10-25 | Ardea Biosciences, Inc. | N-aryl-n'alkyl sulfamides as mek inhibitors |
WO2008034016A2 (en) * | 2006-09-15 | 2008-03-20 | Foldrx Pharmaceuticals, Inc. | Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins |
JP2010513263A (ja) | 2006-12-15 | 2010-04-30 | ファイザー・プロダクツ・インク | ベンズイミダゾール誘導体 |
CN101663279A (zh) | 2007-01-19 | 2010-03-03 | 阿迪生物科学公司 | Mek抑制剂 |
ES2454966T3 (es) | 2007-02-01 | 2014-04-14 | Resverlogix Corp. | Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares |
EA016679B1 (ru) | 2007-04-18 | 2012-06-29 | Пфайзер Продактс Инк. | Сульфониламидные производные для лечения аномального роста клеток |
US8530463B2 (en) | 2007-05-07 | 2013-09-10 | Hale Biopharma Ventures Llc | Multimodal particulate formulations |
UA99731C2 (uk) | 2007-07-30 | 2012-09-25 | Ардеа Биосайенсис, Инк | Кристалічні поліморфні форми n-(ариламіно)сульфонамідів як інгібітори мек, композиція (варіанти) та застосування |
DK2222675T3 (da) | 2007-12-19 | 2013-11-04 | Genentech Inc | 5-anilinoimidazopyridiner og fremgangsmåder til deres anvendelse |
KR20100099185A (ko) | 2007-12-21 | 2010-09-10 | 제넨테크, 인크. | 아자인돌리진 및 이용 방법 |
UA119314C2 (uk) | 2008-01-04 | 2019-06-10 | Інтеллікіне Ллк | Спосіб отримання похідних ізохінолінону (варіанти) |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
DK2271347T3 (en) | 2008-03-28 | 2016-08-15 | Hale Biopharma Ventures Llc | Administration of benzodiazepine compositions |
US8114995B2 (en) | 2008-06-26 | 2012-02-14 | Resverlogix Corp. | Methods of preparing quinazolinone derivatives |
BRPI0915231A2 (pt) | 2008-07-08 | 2018-06-12 | Intellikine Inc | compostos inibidores de quinase e métodos de uso |
EP2147684A1 (en) | 2008-07-22 | 2010-01-27 | Bracco Imaging S.p.A | Diagnostic Agents Selective Against Metalloproteases |
EP2149568A1 (en) | 2008-07-22 | 2010-02-03 | Bracco Imaging S.p.A | Aryl-sulphonamidic dimers as metalloproteases inhibitors |
CA2737597C (en) | 2008-10-16 | 2017-03-14 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof |
US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
ES2542835T3 (es) | 2009-01-08 | 2015-08-12 | Resverlogix Corporation | Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares |
WO2010091150A1 (en) | 2009-02-05 | 2010-08-12 | Immunogen, Inc. | Novel benzodiazepine derivatives |
US20100204221A1 (en) | 2009-02-09 | 2010-08-12 | Hariprasad Vankayalapati | Pyrrolopyrimidinyl axl kinase inhibitors |
JP2012518657A (ja) | 2009-02-25 | 2012-08-16 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 併用抗癌治療 |
US20110171124A1 (en) | 2009-02-26 | 2011-07-14 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the EMT status of tumor cells in vivo |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099363A1 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
JP2012519282A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
WO2010098866A1 (en) | 2009-02-27 | 2010-09-02 | Supergen, Inc. | Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors |
CA3146333A1 (en) | 2009-03-18 | 2010-09-23 | Resverlogix Corp. | Phenyl-quinazolin-4(3h)-one and phenyl-pyrido[2,3-d]pyrimidin-4(3h)-one derivatives and compositions thereof useful as anti-inflammatory agents |
CN102448938A (zh) | 2009-03-27 | 2012-05-09 | 阿迪生物科学公司 | 作为mek抑制剂的二氢吡啶磺酰胺和二氢吡啶硫酰胺 |
ES2821018T3 (es) | 2009-04-22 | 2021-04-23 | Resverlogix Corp | Nuevos agentes antiinflamatorios |
JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン, エルエルシー | 複素環式化合物およびその使用 |
WO2011014726A1 (en) | 2009-07-31 | 2011-02-03 | Osi Pharmaceuticals, Inc. | Mtor inhibitor and angiogenesis inhibitor combination therapy |
WO2011022439A1 (en) | 2009-08-17 | 2011-02-24 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
WO2011027249A2 (en) | 2009-09-01 | 2011-03-10 | Pfizer Inc. | Benzimidazole derivatives |
ES2534358T3 (es) | 2009-10-13 | 2015-04-21 | Allomek Therapeutics, Llc | Inhibidores novedosos de MEK útiles en el tratamiento de enfermedades |
WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
AU2010316780B2 (en) | 2009-11-05 | 2015-07-16 | Rhizen Pharmaceuticals Sa | Novel benzopyran kinase modulators |
WO2011100403A1 (en) | 2010-02-10 | 2011-08-18 | Immunogen, Inc | Cd20 antibodies and uses thereof |
RU2570198C2 (ru) | 2010-02-12 | 2015-12-10 | Пфайзер Инк. | СОЛИ И ПОЛИМОРФЫ 8-ФТОР-2-{4-[(МЕТИЛАМИНО)МЕТИЛ]ФЕНИЛ}-1,3,4,5-ТЕТРАГИДРО-6Н-АЗЕПИНО[5,4,3-cd]ИНДОЛ-6-ОНА |
AU2011223655A1 (en) | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
AU2011223643A1 (en) | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
ES2715611T3 (es) | 2010-05-17 | 2019-06-05 | Incozen Therapeutics Pvt Ltd | Compuestos novedosos de 3H-imidazo[4,5-b]piridina-3,5-disustituida y 3H-[1,2,3]triazolo[4,5-b]piridina 3,5-disustituida como moduladores de proteína cinasas |
WO2011146882A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
ES2695899T3 (es) | 2010-06-16 | 2019-01-11 | Univ Pittsburgh Commonwealth Sys Higher Education | Anticuerpos contra endoplasmina y su uso |
US9738604B2 (en) | 2010-09-03 | 2017-08-22 | Duke University | Ethynylbenzene derivatives |
CA2813162C (en) | 2010-10-20 | 2015-06-16 | Pfizer Inc. | Pyridine-2- derivatives as smoothened receptor modulators |
EP2637669A4 (en) | 2010-11-10 | 2014-04-02 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and their use |
SG10201600179RA (en) | 2011-01-10 | 2016-02-26 | Infinity Pharmaceuticals Inc | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
MX2013008833A (es) | 2011-02-02 | 2013-12-06 | Amgen Inc | Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r). |
EP3053600B1 (en) | 2011-02-15 | 2020-01-29 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
US9127000B2 (en) | 2011-02-23 | 2015-09-08 | Intellikine, LLC. | Heterocyclic compounds and uses thereof |
WO2012142164A1 (en) | 2011-04-12 | 2012-10-18 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii |
US20140178368A1 (en) | 2011-04-19 | 2014-06-26 | Leslie Lynne SHARP | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
JP2014519813A (ja) | 2011-04-25 | 2014-08-21 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用 |
ES2710874T3 (es) | 2011-05-04 | 2019-04-29 | Rhizen Pharmaceuticals S A | Compuestos novedosos como moduladores de proteína cinasas |
DK3415139T3 (da) | 2011-06-14 | 2022-06-20 | Neurelis Inc | Administration af benzodiazepin |
WO2013012918A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
EP2734520B1 (en) | 2011-07-19 | 2016-09-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9416132B2 (en) | 2011-07-21 | 2016-08-16 | Tolero Pharmaceuticals, Inc. | Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors |
AU2012302197B2 (en) | 2011-08-29 | 2016-01-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
AU2012310157B2 (en) | 2011-09-16 | 2015-11-12 | Pfizer Inc. | Solid forms of a transthyretin dissociation inhibitor |
UA110259C2 (uk) | 2011-09-22 | 2015-12-10 | Пфайзер Інк. | Похідні піролопіримідину і пурину |
WO2013049332A1 (en) | 2011-09-29 | 2013-04-04 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
US9783613B2 (en) | 2011-10-04 | 2017-10-10 | Igem Therapeutics Limited | IgE anti-HMW-MAA antibody |
RS58911B1 (sr) | 2011-11-01 | 2019-08-30 | Resverlogix Corp | Oralne formulacije sa trenutnim otpuštanjem za supstituisane hinazolinone |
RU2014114015A (ru) | 2011-11-08 | 2015-12-20 | Пфайзер Инк. | Способы лечения воспалительных расстройств с использованием антител против m-csf |
EP2817004B1 (en) | 2012-02-22 | 2018-04-11 | The Regents of The University of Colorado, A Body Corporate | Bouvardin derivatives and therapeutic uses thereof |
US9452215B2 (en) | 2012-02-22 | 2016-09-27 | The Regents Of The University Of Colorado | Bourvadin derivatives and therapeutic uses thereof |
SG11201406185WA (en) | 2012-03-30 | 2014-11-27 | Rhizen Pharmaceuticals Sa | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
SI2859017T1 (sl) | 2012-06-08 | 2019-05-31 | Sutro Biopharma, Inc. | Protitelesa, ki vsebujejo specifične nenaravne aminokislinske ostanke, postopki njihove priprave in postopki njihove uporabe |
EP3135690A1 (en) | 2012-06-26 | 2017-03-01 | Sutro Biopharma, Inc. | Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
EP2887965A1 (en) | 2012-08-22 | 2015-07-01 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
PL3584255T3 (pl) | 2012-08-31 | 2022-05-16 | Sutro Biopharma, Inc. | Modyfikowane aminokwasy zawierające grupę azydkową |
DK2909181T3 (da) | 2012-10-16 | 2017-11-20 | Tolero Pharmaceuticals Inc | PKM2-modulatorer og fremgangsmåder til anvendelse deraf |
DK2914296T4 (da) | 2012-11-01 | 2022-01-03 | Infinity Pharmaceuticals Inc | Behandling af cancere under anvendelse af PI3-kinase-isoform-modulatorer |
US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
US9271978B2 (en) | 2012-12-21 | 2016-03-01 | Zenith Epigenetics Corp. | Heterocyclic compounds as bromodomain inhibitors |
JP6494533B2 (ja) | 2013-02-28 | 2019-04-03 | イミュノジェン・インコーポレーテッド | 細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体 |
JP6423804B2 (ja) | 2013-02-28 | 2018-11-14 | イミュノジェン・インコーポレーテッド | 細胞結合剤及び細胞毒性剤を含む複合体 |
MX2015012062A (es) | 2013-03-14 | 2016-05-05 | Tolero Pharmaceuticals Inc | Inhibidores de jak2 y alk2 y metodos para su uso. |
CA2906542A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
AU2014239542A1 (en) | 2013-03-15 | 2015-10-01 | Araxes Pharma Llc | Covalent inhibitors of KRas G12C |
WO2014151386A1 (en) | 2013-03-15 | 2014-09-25 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
BR112015029969A2 (pt) | 2013-05-30 | 2017-07-25 | Infinity Pharmaceuticals Inc | tratamento de câncer usando moduladores de isoformas quinase pi3 |
WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
US9764039B2 (en) | 2013-07-10 | 2017-09-19 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
AU2014306451B2 (en) | 2013-08-16 | 2019-01-17 | Duke University | Substituted hydroxamic acid compounds |
WO2015024016A2 (en) | 2013-08-16 | 2015-02-19 | Duke University | 2-piperidinyl substituted n,3-dihydroxybutanamides |
US10189786B2 (en) | 2013-08-16 | 2019-01-29 | Duke University | Antibacterial compounds |
EA032196B1 (ru) | 2013-10-03 | 2019-04-30 | Кура Онколоджи, Инк. | Ингибиторы erk и способы применения |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
TWI657085B (zh) | 2013-10-04 | 2019-04-21 | 英菲尼提製藥股份有限公司 | 雜環化合物及其用途 |
AU2014331794C1 (en) | 2013-10-10 | 2019-09-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C |
TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Kras g12c之抑制劑 |
US9840493B2 (en) | 2013-10-11 | 2017-12-12 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
WO2015061204A1 (en) | 2013-10-21 | 2015-04-30 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
WO2015155624A1 (en) | 2014-04-10 | 2015-10-15 | Pfizer Inc. | Dihydropyrrolopyrimidine derivatives |
WO2015168079A1 (en) | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Pyrimidine or pyridine derivatives useful as pi3k inhibitors |
CR20160497A (es) | 2014-04-30 | 2016-12-20 | Pfizer | Derivados de diheterociclo enlazado a cicloalquilo |
EP3778584A1 (en) | 2014-06-19 | 2021-02-17 | ARIAD Pharmaceuticals, Inc. | Production process of 2-chloro-4-heteroaryl-pyrimidine derivatives |
WO2016001789A1 (en) | 2014-06-30 | 2016-01-07 | Pfizer Inc. | Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer |
ES2925224T3 (es) | 2014-07-31 | 2022-10-14 | Us Gov Health & Human Services | Anticuerpos monoclonales humanos contra EphA4 y su uso |
JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
JP2017528498A (ja) | 2014-09-25 | 2017-09-28 | アラクセス ファーマ エルエルシー | Kras g12c変異体タンパク質のインヒビター |
WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
EP3233829B1 (en) | 2014-12-18 | 2019-08-14 | Pfizer Inc | Pyrimidine and triazine derivatives and their use as axl inhibitors |
CA2977308A1 (en) | 2015-03-13 | 2016-09-22 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
CA2981530A1 (en) | 2015-04-10 | 2016-10-13 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
US10428064B2 (en) | 2015-04-15 | 2019-10-01 | Araxes Pharma Llc | Fused-tricyclic inhibitors of KRAS and methods of use thereof |
AU2016252609B2 (en) | 2015-04-20 | 2022-06-30 | Sumitomo Pharma Oncology, Inc. | Predicting response to alvocidib by mitochondrial profiling |
US10011629B2 (en) | 2015-05-01 | 2018-07-03 | Cocrystal Pharma, Inc. | Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer |
TR201911032T4 (tr) | 2015-05-18 | 2019-08-21 | Tolero Pharmaceuticals Inc | Artırılmış biyoyararlanıma sahip alvocıdıb ön ilaçları. |
AR104020A1 (es) | 2015-06-04 | 2017-06-21 | Kura Oncology Inc | Métodos y composiciones para inhibir la interacción de menina con proteínas mill |
WO2017009751A1 (en) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
RU2759963C2 (ru) | 2015-08-03 | 2021-11-19 | Сумитомо Даиниппон Фарма Онколоджи, Инк. | Комбинированные терапии для лечения рака |
EP3356353A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
WO2017058805A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10689356B2 (en) | 2015-09-28 | 2020-06-23 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
EP3356349A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
WO2017070256A2 (en) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Method for screening inhibitors of ras |
TW201726656A (zh) | 2015-11-16 | 2017-08-01 | 亞瑞克西斯製藥公司 | 包含經取代雜環基團之2-經取代喹唑啉化合物及其使用方法 |
US20180371551A1 (en) | 2015-12-03 | 2018-12-27 | Agios Pharmaceuticals, Inc. | Mat2a inhibitors for treating mtap null cancer |
WO2017100546A1 (en) | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
SG11201806419RA (en) | 2016-01-27 | 2018-08-30 | Sutro Biopharma Inc | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates |
JP6919977B2 (ja) | 2016-03-16 | 2021-08-18 | クラ オンコロジー,インク. | メニン−mllの置換された阻害剤及びその使用方法 |
AU2017235462B2 (en) | 2016-03-16 | 2021-07-01 | Kura Oncology, Inc. | Bridged bicyclic inhibitors of menin-MLL and methods of use |
US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
WO2017197240A1 (en) | 2016-05-12 | 2017-11-16 | The Regents Of The University Of Michigan | Ash1l inhibitors and methods of treatment therewith |
US11118233B2 (en) | 2016-05-18 | 2021-09-14 | The University Of Chicago | BTK mutation and ibrutinib resistance |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
EP3507305A1 (en) | 2016-09-02 | 2019-07-10 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating b cell disorders |
US10280172B2 (en) | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
RU2632703C1 (ru) * | 2016-12-12 | 2017-10-09 | федеральное государственное автономное образовательное учреждение высшего образования "Южный федеральный университет" | Средство для ингибирования метастазирования в легких |
WO2018119000A1 (en) | 2016-12-19 | 2018-06-28 | Tolero Pharmaceuticals, Inc. | Profiling peptides and methods for sensitivity profiling |
UA124474C2 (uk) | 2016-12-22 | 2021-09-22 | Емджен Інк. | БЕНЗІЗОТІАЗОЛЬНІ, ІЗОТІАЗОЛО[3,4-b]ПІРИДИНОВІ, ХІНАЗОЛІНОВІ, ФТАЛАЗИНОВІ, ПІРИДО[2,3-d]ПІРИДАЗИНОВІ Й ПІРИДО[2,3-d]ПІРИМІДИНОВІ ПОХІДНІ ЯК ІНГІБІТОРИ G12C KRAS ДЛЯ ЛІКУВАННЯ РАКУ ЛЕГЕНІ, РАКУ ПІДШЛУНКОВОЇ ЗАЛОЗИ АБО КОЛОРЕКТАЛЬНОГО РАКУ |
EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
EP3573964A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Benzothiophene and benzothiazole compounds and methods of use thereof |
CN110382482A (zh) | 2017-01-26 | 2019-10-25 | 亚瑞克西斯制药公司 | 稠合的杂-杂二环化合物及其使用方法 |
CN110461872B (zh) | 2017-01-26 | 2023-09-26 | 再鼎医药(上海)有限公司 | Cd47抗原结合单元及其用途 |
EP3573970A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
US11274093B2 (en) | 2017-01-26 | 2022-03-15 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
US20200385364A1 (en) | 2017-01-26 | 2020-12-10 | Araxes Pharma Llc | Fused n-heterocyclic compounds and methods of use thereof |
EP3601249A4 (en) | 2017-03-24 | 2020-12-16 | Kura Oncology, Inc. | METHODS OF TREATMENT OF MALIGNANT HEMOPATHIES AND EWING'S SARCOMA |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
EP3630746A1 (en) | 2017-05-25 | 2020-04-08 | Araxes Pharma LLC | Compounds and methods of use thereof for treatment of cancer |
AU2018271990A1 (en) | 2017-05-25 | 2019-12-12 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
EP3630747A1 (en) | 2017-05-25 | 2020-04-08 | Araxes Pharma LLC | Quinazoline derivatives as modulators of mutant kras, hras or nras |
US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
US20200207859A1 (en) | 2017-07-26 | 2020-07-02 | Sutro Biopharma, Inc. | Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma |
IL293443A (en) | 2017-09-08 | 2022-07-01 | Amgen Inc | kras g12c inhibitors and methods of using them |
WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
EP3684814A1 (en) | 2017-09-18 | 2020-07-29 | Sutro Biopharma, Inc. | Anti-folate receptor alpha antibody conjugates and their uses |
US11649251B2 (en) | 2017-09-20 | 2023-05-16 | Kura Oncology, Inc. | Substituted inhibitors of menin-MLL and methods of use |
WO2019075367A1 (en) | 2017-10-13 | 2019-04-18 | Tolero Pharmaceuticals, Inc. | PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER |
EP3706737A4 (en) | 2017-11-10 | 2021-10-20 | The Regents of the University of Michigan | ASH11 INHIBITORS AND METHOD OF TREATING THEREOF |
CA3084809A1 (en) | 2017-12-07 | 2019-06-13 | The Regents Of The University Of Michigan | Nsd family inhibitors and methods of treatment therewith |
BR112020020246A8 (pt) | 2018-04-05 | 2022-10-18 | Sumitomo Dainippon Pharma Oncology Inc | Inibidores de cinase axl e uso dos mesmos |
JP7361722B2 (ja) | 2018-05-04 | 2023-10-16 | アムジエン・インコーポレーテツド | Kras g12c阻害剤及び同一物の使用方法 |
US11090304B2 (en) | 2018-05-04 | 2021-08-17 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
CA3099045A1 (en) | 2018-05-10 | 2019-11-14 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
JP7360396B2 (ja) | 2018-06-01 | 2023-10-12 | アムジエン・インコーポレーテツド | Kras g12c阻害剤及び同一物の使用方法 |
EP4155293A1 (en) | 2018-06-07 | 2023-03-29 | The Regents of The University of Michigan | Prc1 inhibitors and methods of treatment therewith |
EP4268898A3 (en) | 2018-06-11 | 2024-01-17 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
MX2020012261A (es) | 2018-06-12 | 2021-03-31 | Amgen Inc | Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer. |
AU2019310590A1 (en) | 2018-07-26 | 2021-01-14 | Sumitomo Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
JP2021532157A (ja) | 2018-08-01 | 2021-11-25 | アラクセス ファーマ エルエルシー | がんを処置するための複素環式スピロ化合物およびその使用方法 |
EP3852811A1 (en) | 2018-09-17 | 2021-07-28 | Sutro Biopharma, Inc. | Combination therapies with anti-folate receptor antibody conjugates |
JP2022505835A (ja) | 2018-10-24 | 2022-01-14 | アラクセス ファーマ エルエルシー | 腫瘍転移を阻害するためのg12c変異体krasタンパク質の阻害剤としての2-(2-アクリロイル-2,6-ジアザスピロ[3.4]オクタン-6-イル)-6-(1h-インダゾール-4-イル)-ベンゾニトリル誘導体および関連化合物 |
JP2020090482A (ja) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
MA55136A (fr) | 2018-11-19 | 2022-02-23 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
EP3887373A1 (en) | 2018-11-29 | 2021-10-06 | Araxes Pharma LLC | Compounds and methods of use thereof for treatment of cancer |
CN113490499A (zh) | 2018-12-04 | 2021-10-08 | 大日本住友制药肿瘤公司 | 用作治疗癌症的活性剂的cdk9抑制剂及其多晶型物 |
US20220002311A1 (en) | 2018-12-20 | 2022-01-06 | Amgen Inc. | Kif18a inhibitors |
MX2021007158A (es) | 2018-12-20 | 2021-08-16 | Amgen Inc | Heteroarilamidas utiles como inhibidores de kif18a. |
US11236069B2 (en) | 2018-12-20 | 2022-02-01 | Amgen Inc. | KIF18A inhibitors |
MX2021007104A (es) | 2018-12-20 | 2021-08-11 | Amgen Inc | Inhibidores de kif18a. |
KR20210146290A (ko) | 2019-02-12 | 2021-12-03 | 스미토모 다이니폰 파마 온콜로지, 인크. | 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제 |
WO2020180768A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
MX2021010323A (es) | 2019-03-01 | 2021-12-10 | Revolution Medicines Inc | Compuestos bicíclicos de heterociclilo y usos de este. |
JP2022525149A (ja) | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置 |
AU2020245437A1 (en) | 2019-03-22 | 2021-09-30 | Sumitomo Pharma Oncology, Inc. | Compositions comprising PKM2 modulators and methods of treatment using the same |
WO2020227105A1 (en) | 2019-05-03 | 2020-11-12 | Sutro Biopharma, Inc. | Anti-bcma antibody conjugates |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
EP3972973A1 (en) | 2019-05-21 | 2022-03-30 | Amgen Inc. | Solid state forms |
CN114302878A (zh) | 2019-07-03 | 2022-04-08 | 大日本住友制药肿瘤公司 | 酪氨酸激酶非受体1(tnk1)抑制剂及其用途 |
CN114269731A (zh) | 2019-08-02 | 2022-04-01 | 美国安进公司 | Kif18a抑制剂 |
JP2022542319A (ja) | 2019-08-02 | 2022-09-30 | アムジエン・インコーポレーテツド | Kif18a阻害剤 |
MX2022001295A (es) | 2019-08-02 | 2022-02-22 | Amgen Inc | Inhibidores de kif18a. |
US20220372018A1 (en) | 2019-08-02 | 2022-11-24 | Amgen Inc. | Kif18a inhibitors |
EP4031542A4 (en) | 2019-09-18 | 2023-10-25 | Merck Sharp & Dohme LLC | KRAS G12C MUTANT SMALL MOLECULE INHIBITORS |
TW202126636A (zh) | 2019-09-30 | 2021-07-16 | 美商阿吉歐斯製藥公司 | 作為menin抑制劑之六氫吡啶化合物 |
JP2022552873A (ja) | 2019-10-24 | 2022-12-20 | アムジエン・インコーポレーテツド | がんの治療におけるkras g12c及びkras g12d阻害剤として有用なピリドピリミジン誘導体 |
CA3158793A1 (en) | 2019-10-28 | 2021-05-06 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
JP2023515235A (ja) | 2019-10-31 | 2023-04-12 | 大鵬薬品工業株式会社 | 4-アミノブタ-2-エンアミド誘導体及びその塩 |
EP4054719A1 (en) | 2019-11-04 | 2022-09-14 | Revolution Medicines, Inc. | Ras inhibitors |
CR20220243A (es) | 2019-11-04 | 2022-08-04 | Revolution Medicines Inc | Inhibidores de ras |
TW202132315A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ras 抑制劑 |
EP4055017A1 (en) | 2019-11-08 | 2022-09-14 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
AR120456A1 (es) | 2019-11-14 | 2022-02-16 | Amgen Inc | Síntesis mejorada del compuesto inhibidor de g12c de kras |
KR20220101125A (ko) | 2019-11-14 | 2022-07-19 | 암젠 인크 | Kras g12c 억제제 화합물의 개선된 합성 |
WO2021108683A1 (en) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
MX2022008305A (es) | 2020-01-07 | 2022-08-08 | Revolution Medicines Inc | Dosificacion de inhibidores de shp2 y metodos de tratamiento del cancer. |
WO2021155006A1 (en) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibitors of cyclin-dependent kinases and uses thereof |
US20230095053A1 (en) | 2020-03-03 | 2023-03-30 | Sutro Biopharma, Inc. | Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use |
TW202204334A (zh) | 2020-04-08 | 2022-02-01 | 美商阿吉歐斯製藥公司 | Menin抑制劑及治療癌症之使用方法 |
WO2021204159A1 (en) | 2020-04-08 | 2021-10-14 | Agios Pharmaceuticals, Inc. | Menin inhibitors and methods of use for treating cancer |
US20230181536A1 (en) | 2020-04-24 | 2023-06-15 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c |
US20230174518A1 (en) | 2020-04-24 | 2023-06-08 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
CA3185209A1 (en) | 2020-07-10 | 2021-01-27 | Alyssa WINKLER | Gas41 inhibitors and methods of use thereof |
US20230255972A1 (en) | 2020-07-15 | 2023-08-17 | Taiho Pharmaceutical Co., Ltd. | Pyrimidine compound-containing combination to be used in tumor treatment |
IL301062A (en) | 2020-09-03 | 2023-05-01 | Revolution Medicines Inc | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
EP4214209A1 (en) | 2020-09-15 | 2023-07-26 | Revolution Medicines, Inc. | Indole derivatives as ras inhibitors in the treatment of cancer |
TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk﹘5抑制劑和彼之用途 |
EP4267250A1 (en) | 2020-12-22 | 2023-11-01 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
PE20240327A1 (es) | 2021-04-13 | 2024-02-22 | Nuvalent Inc | Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr |
WO2022232488A1 (en) | 2021-04-30 | 2022-11-03 | Celgene Corporation | Combination therapies using an anti-bcma antibody drug conjugate (adc) in combination with a gamma secretase inhibitor (gsi) |
BR112023022819A2 (pt) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Compostos, composição farmacêutica, conjugados e métodos para tratar câncer em um sujeito, para tratar um distúrbio e para inibir uma proteína ras em uma célula |
CR20230558A (es) | 2021-05-05 | 2024-01-24 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cáncer |
WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
CN117769554A (zh) | 2021-05-28 | 2024-03-26 | 大鹏药品工业株式会社 | Kras突变蛋白的小分子抑制剂 |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
WO2023056589A1 (en) | 2021-10-08 | 2023-04-13 | Servier Pharmaceuticals Llc | Menin inhibitors and methods of use for treating cancer |
TW202340214A (zh) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | 做為shp2抑制劑之吡唑并吡𠯤化合物 |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023211812A1 (en) | 2022-04-25 | 2023-11-02 | Nested Therapeutics, Inc. | Heterocyclic derivatives as mitogen-activated protein kinase (mek) inhibitors |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2024006542A1 (en) | 2022-06-30 | 2024-01-04 | Sutro Biopharma, Inc. | Anti-ror1 antibodies and antibody conjugates, compositions comprising anti-ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates |
WO2024010925A2 (en) | 2022-07-08 | 2024-01-11 | Nested Therapeutics, Inc. | Mitogen-activated protein kinase (mek) inhibitors |
WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5646167A (en) * | 1993-01-06 | 1997-07-08 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamix acids |
JPH09500134A (ja) * | 1993-07-16 | 1997-01-07 | メルク エンド カンパニー インコーポレーテッド | ベンゾオキサジノンおよびベンゾピリミジノンピペリジニル早産防止オキシトシン受容体拮抗剤 |
ATE225343T1 (de) * | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
US6172057B1 (en) * | 1997-02-27 | 2001-01-09 | American Cyanamid Company | N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
IL131258A0 (en) | 1997-02-27 | 2001-01-28 | American Cyanamid Co | N-hydroxy-2-(alkyl aryl or heteroaryl sulfanyl sulfinyl or sulfonyl)-3-substituted alkyl aryl or heteroarylamides as matrix metalloproteinase inhibitors |
CA2255284A1 (en) * | 1997-12-22 | 1999-06-22 | Forschungszentrum Julich Gmbh | Unicellular or multicellular organisms for preparing riboflavin |
GB9801690D0 (en) * | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
-
1997
- 1997-12-05 GB GBGB9725782.8A patent/GB9725782D0/en not_active Ceased
-
1998
- 1998-09-10 UA UA2000053127A patent/UA52791C2/uk unknown
- 1998-10-09 NZ NZ504421A patent/NZ504421A/en unknown
- 1998-10-09 HU HU0100845A patent/HUP0100845A3/hu unknown
- 1998-10-09 EA EA200000481A patent/EA002882B1/ru not_active IP Right Cessation
- 1998-10-09 CA CA002312935A patent/CA2312935C/en not_active Expired - Fee Related
- 1998-10-09 CN CN98811874A patent/CN1281433A/zh active Pending
- 1998-10-09 DE DE69820906T patent/DE69820906T2/de not_active Expired - Fee Related
- 1998-10-09 PT PT98955494T patent/PT1036062E/pt unknown
- 1998-10-09 PL PL98341031A patent/PL341031A1/xx unknown
- 1998-10-09 ES ES98955494T patent/ES2212373T3/es not_active Expired - Lifetime
- 1998-10-09 EP EP98955494A patent/EP1036062B1/en not_active Expired - Lifetime
- 1998-10-09 WO PCT/EP1998/006640 patent/WO1999029667A1/en not_active Application Discontinuation
- 1998-10-09 IL IL13630098A patent/IL136300A0/xx unknown
- 1998-10-09 AT AT98955494T patent/ATE257151T1/de not_active IP Right Cessation
- 1998-10-09 SK SK782-2000A patent/SK7822000A3/sk unknown
- 1998-10-09 CZ CZ20002037A patent/CZ20002037A3/cs unknown
- 1998-10-09 AU AU12301/99A patent/AU741859B2/en not_active Ceased
- 1998-10-09 YU YU32100A patent/YU32100A/sh unknown
- 1998-10-09 US US09/423,359 patent/US6495568B1/en not_active Expired - Fee Related
- 1998-10-09 BR BR9813360-8A patent/BR9813360A/pt not_active Application Discontinuation
- 1998-10-09 ID IDW20001046A patent/ID24626A/id unknown
- 1998-10-09 KR KR10-2000-7006098A patent/KR100372990B1/ko not_active IP Right Cessation
- 1998-10-09 DK DK98955494T patent/DK1036062T3/da active
- 1998-10-09 JP JP2000524264A patent/JP3445242B2/ja not_active Expired - Fee Related
- 1998-10-09 TR TR2000/01611T patent/TR200001611T2/xx unknown
- 1998-11-20 PA PA19988463501A patent/PA8463501A1/es unknown
- 1998-11-25 GT GT199800189A patent/GT199800189A/es unknown
- 1998-12-01 PE PE1998001166A patent/PE133999A1/es not_active Application Discontinuation
- 1998-12-02 TN TNTNSN98216A patent/TNSN98216A1/fr unknown
- 1998-12-02 DZ DZ980276A patent/DZ2666A1/xx active
- 1998-12-02 MA MA25365A patent/MA26571A1/fr unknown
- 1998-12-03 UY UY25282A patent/UY25282A1/es not_active IP Right Cessation
- 1998-12-03 UY UY25280A patent/UY25280A1/es not_active IP Right Cessation
- 1998-12-03 AP APAP/P/1998/001412A patent/AP930A/en active
- 1998-12-03 AR ARP980106144A patent/AR016429A1/es not_active Application Discontinuation
- 1998-12-04 ZA ZA9811112A patent/ZA9811112B/xx unknown
-
2000
- 2000-05-19 IS IS5503A patent/IS5503A/is unknown
- 2000-05-31 OA OA1200000160A patent/OA11388A/en unknown
- 2000-06-02 NO NO20002826A patent/NO20002826L/no not_active Application Discontinuation
- 2000-06-05 BG BG104506A patent/BG104506A/bg unknown
- 2000-06-05 HR HR20000373A patent/HRP20000373A2/hr not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20000373A2 (en) | Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors | |
EP0363963B1 (en) | Piperidinyl benzimidazoles as antihistamines | |
EP2344471B1 (en) | 7-piperidinoalkyl-3,4-dihydroquinolone derivative | |
US5843988A (en) | Cyclopropachromencarboxylic acid derivatives | |
US7005432B2 (en) | Substituted imidazol-pyridazine derivatives | |
US5705505A (en) | Cyclic amide derivatives for treating asthma | |
JP2004520347A (ja) | Ldl−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体 | |
MXPA01012450A (es) | Inhibidores de metaloproteasas. | |
EP1259484B1 (en) | Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion | |
JP4416198B2 (ja) | アニリド誘導体、その製造法および用途 | |
SU747424A3 (ru) | Способ получени -арил- (1- -4-пиперидинил) ацетамидов или их солей | |
US5182399A (en) | Process for preparing piperidinyl benzimidazoles | |
WO2001005767A1 (en) | Organic compounds | |
MXPA00005520A (en) | Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors | |
JP3201194B2 (ja) | アミド誘導体 | |
KR20010013435A (ko) | 5-나프탈렌-1-일-1,3-디옥산 유도체, 제조 및 치료에의 이용 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
ODBC | Application rejected |